Retrieve available abstracts of 504 articles: HTML format
Single Articles
July 2025
RING A, Sutherland S, Harper-Wynne C, Owen J, et al A disease registry study to prospectively observe treatment patterns and outcomes
in patients with HER2-positive unresectable LA/MBC: final results of the ESTHER
study.
Breast Cancer Res Treat. 2025;212:113-121. PubMedAbstract available
NIERENBERG TC, Thomas SM, Halliday I, Botty van den Bruele A, et al Survival outcomes after pathologic complete response with neoadjuvant endocrine
therapy vs. neoadjuvant chemotherapy: a retrospective national database study.
Breast Cancer Res Treat. 2025;212:161-172. PubMedAbstract available
COSAR R, Sut N Our response to the letter to the editor for the article "Comparison of survival
between unilateral and bilateral breast cancers using propensity score matching:
a retrospective single-center analysis".
Breast Cancer Res Treat. 2025;212:185-186. PubMedAbstract available
JASPER JM, Vora H, Kantor O, McGrath M, et al Management of ipsilateral breast tumor recurrence after prior breast conservation
therapy.
Breast Cancer Res Treat. 2025;212:361-369. PubMedAbstract available
AKTAS A, Gurleyik MG, Akkus D, Ucur Z, et al Invasive lobular breast carcinoma variants; clinicopathological features and
patient outcomes.
Breast Cancer Res Treat. 2025;212:347-359. PubMedAbstract available
YAO J, Zhou W, Jia X, Zhu Y, et al Machine learning prediction of pathological complete response to neoadjuvant
chemotherapy with peritumoral breast tumor ultrasound radiomics: compare with
intratumoral radiomics and clinicopathologic predictors.
Breast Cancer Res Treat. 2025;212:325-336. PubMedAbstract available
YI ZL, Yang BB, Zhang JN, Zhao MJ, et al Radiation recall dermatitis induced by abemaciclib with successful rechallenge: a
case series and literature review.
Breast Cancer Res Treat. 2025;212:189-193. PubMedAbstract available
June 2025
LIUTTI VT, do Vale DL, de Souza BL, Manea RRF, et al Neoadjuvant dose-dense anthracycline and cyclophosphamide in combination with
carboplatin, paclitaxel, and pembrolizumab for triple-negative breast cancer: a
systematic review and meta-analysis.
Breast Cancer Res Treat. 2025 Jun 13. doi: 10.1007/s10549-025-07746. PubMedAbstract available
HANNOUN-LEVI JM, Strnad V, Polgar C Local treatment of ipsilateral breast cancer recurrence: a sensitive
decision-making process.
Breast Cancer Res Treat. 2025 Jun 12. doi: 10.1007/s10549-025-07761. PubMed
SHIN E, Cha YJ, Kim HM, Koo JS, et al PD-L1 22C3 CPS in paired primary breast cancer and lung metastasis.
Breast Cancer Res Treat. 2025 Jun 11. doi: 10.1007/s10549-025-07757. PubMedAbstract available
STENMARK TULLBERG A, Thurfjell V, Kovacs A, Micke P, et al Tumoral pSMAD2 as a prognostic biomarker in early-stage breast cancer: insights
from the randomized SweBCG91RT trial.
Breast Cancer Res Treat. 2025 Jun 9. doi: 10.1007/s10549-025-07744. PubMedAbstract available
ULENE SR, Wang S, Cook JR, McAuley F, et al Continuous glucose monitoring to characterize hyperglycemia during chemotherapy
for early stage breast cancer.
Breast Cancer Res Treat. 2025 Jun 4. doi: 10.1007/s10549-025-07745. PubMedAbstract available
LEE KT, Hu B, Martinez Tyson D, Geiss C, et al A mixed-methods study characterizing experiences of medical oncologists' use of
gonadotropin-releasing hormone agonists for treatment of breast cancer.
Breast Cancer Res Treat. 2025 Jun 3. doi: 10.1007/s10549-025-07734. PubMedAbstract available
COHEN LN, Rogers CC, Lloren JIC, Kamaraju S, et al National trends in neoadjuvant systemic therapy utilization in patients with
early-stage HER2-positive breast cancer from 2016-2021: The impact of the
KATHERINE trial.
Breast Cancer Res Treat. 2025 Jun 3. doi: 10.1007/s10549-025-07750. PubMedAbstract available
WING SE, Liu Y, Zheng F, Hamm NC, et al Insurer and patient costs for repeat breast surgery after initial lumpectomy for
breast cancer.
Breast Cancer Res Treat. 2025 Jun 3. doi: 10.1007/s10549-025-07735. PubMedAbstract available
DING K, Chen L, Levine KM, Sikora MJ, et al FGFR4 in endocrine resistance: overexpression and estrogen regulation without
direct causative role.
Breast Cancer Res Treat. 2025;211:501-515. PubMedAbstract available
HAN R, Brogi E, Thompson D, El-Tamer M, et al Oncotype DX recurrence score in node-positive patients in the post-RxPONDER era:
a single-institution experience.
Breast Cancer Res Treat. 2025;211:449-454. PubMedAbstract available
BOTTY VAN DEN BRUELE A, Ren Y, Thomas SM, Ntowe KW, et al High risk surveillance MRI may not be necessary in BRCA1/2 mutation carriers over
70 years old.
Breast Cancer Res Treat. 2025;211:421-429. PubMedAbstract available
COLCIAGO RR, Ferrario F, Chissotti C, Rossano G, et al Long-term outcomes of volume de-escalation for breast nodal irradiation.
Breast Cancer Res Treat. 2025;211:375-384. PubMedAbstract available
DUGGIRALA N, Zhang S, Master A, Rao R, et al Biology, care, and outcomes of gestational breast cancers: a review.
Breast Cancer Res Treat. 2025;211:547-559. PubMedAbstract available
NEWMAN AM, Daly AE, Anderman KJ, Dang PA, et al Timing of radiofrequency identification tag placement: can early placement save
time and patient experience?
Breast Cancer Res Treat. 2025;211:669-674. PubMedAbstract available
ZHANG C, Liu J, Gu T, Meng X, et al Enhanced antitumor efficacy of bispecific antibody blocking PD-L1 and LAG-3 with
doxorubicin: mechanism and safety evaluation.
Breast Cancer Res Treat. 2025;211:637-648. PubMedAbstract available
BUZATTO IPC, Recife SA, Miguel L, Bonini RM, et al Machine learning can reliably predict malignancy of breast lesions based on
clinical and ultrasonographic features.
Breast Cancer Res Treat. 2025;211:581-593. PubMedAbstract available
WEHBE A, Katlin F, Sharma E, Hans M, et al Breast imaging recommendations for young females (age < 40 years) with >/= 20%
lifetime breast cancer risk: practice patterns at a specialized clinic.
Breast Cancer Res Treat. 2025 Jun 1. doi: 10.1007/s10549-025-07738. PubMedAbstract available
May 2025
MUSTAFA NM, Mustafa MT, Abushanab AK, Alakhras HM, et al Efficacy and safety of entinostat plus exemestane in hormone receptor-positive
breast cancer: a systematic review meta-analysis of randomized controlled trials.
Breast Cancer Res Treat. 2025 May 31. doi: 10.1007/s10549-025-07737. PubMedAbstract available
BADER G, Quintanilha JCF, Veney D, Graf RP, et al Utility of plasma circulating DNA tumor fraction in bone-only metastatic breast
cancer: a real-world outcomes study.
Breast Cancer Res Treat. 2025 May 30. doi: 10.1007/s10549-025-07740. PubMedAbstract available
MEDFORD AJ, Velimirovic M, Gefen Y, Niemierko A, et al Genomic and proteomic profiling of GATA3 mutant metastatic hormone
receptor-positive breast cancer and impact on clinical outcomes.
Breast Cancer Res Treat. 2025 May 29. doi: 10.1007/s10549-025-07710. PubMedAbstract available
GEMMILL JAL, Thompson P, Batiste R, Vacchi-Suzzi C, et al Metastatic breast cancer through the Oncotype DX Breast Recurrence Score(R):
insights from a small cohort study.
Breast Cancer Res Treat. 2025 May 28. doi: 10.1007/s10549-025-07736. PubMedAbstract available
SPRIET J, Miled AB, Mailliez A, Bonnier S, et al Breast magnetic resonance imaging patterns of tumor regression after neoadjuvant
chemotherapy and immunotherapy in early triple-negative breast cancer patients:
prediction of pathological response and performance of ultrafast sequences.
Breast Cancer Res Treat. 2025 May 28. doi: 10.1007/s10549-025-07650. PubMedAbstract available
FREITAS AJA, Causin RL, Calfa S, Santana IVV, et al Exploring the Nottingham classification: assessing gene expression profiles in
breast cancer patients and their association with outcomes.
Breast Cancer Res Treat. 2025 May 28. doi: 10.1007/s10549-025-07718. PubMedAbstract available
SIREK A, Sirek T, Nowakowski R, Borawski P, et al Subtype-specific dysregulation of biogenic amine-related genes and miRNAs in
breast cancer: identification of DRD2, HRH2, and HRH4 as potential therapeutic
targets in TNBC and HER2+ subtypes.
Breast Cancer Res Treat. 2025 May 27. doi: 10.1007/s10549-025-07732. PubMedAbstract available
KOSTOV AM, Jensen MB, Ejlertsen B, Thomassen M, et al Timely germline BRCA testing after invasive breast cancer promotes contralateral
risk-reducing mastectomy and improves survival: an observational retrospective
study.
Breast Cancer Res Treat. 2025 May 23. doi: 10.1007/s10549-025-07726. PubMedAbstract available
GRACIANO N, Lopez L, Rodriguez CA, Montoya K, et al Effect of chemotherapy timing in triple-negative breast cancer: a real-world
evidence study.
Breast Cancer Res Treat. 2025 May 21. doi: 10.1007/s10549-025-07716. PubMedAbstract available
WADDEN E, Yogeswaran V, Ray RM, Vasbinder A, et al Social determinants of cardiovascular disease in women with and without breast
cancer.
Breast Cancer Res Treat. 2025 May 21. doi: 10.1007/s10549-025-07731. PubMedAbstract available
LORENTZEN EH, Chen YJ, Jones AL, Kantor O, et al Omission of multimodal therapy in older adults with high-risk breast cancer.
Breast Cancer Res Treat. 2025 May 20. doi: 10.1007/s10549-025-07728. PubMedAbstract available
ARIF S, Muhammad N, Ang BH, Naeemi H, et al Predicting the likelihood of carrying BRCA1 or BRCA2 pathogenic variants in
high-risk Pakistani breast cancer patients.
Breast Cancer Res Treat. 2025 May 20. doi: 10.1007/s10549-025-07724. PubMedAbstract available
PEREZ-MORENO E, Ortega-Hernandez V, Zavala VA, Gamboa J, et al Suppression of breast cancer metastatic behavior by microRNAs targeting EMT
transcription factors. A relevant participation of miR-196a-5p and miR-22-3p in
ZEB1 expression.
Breast Cancer Res Treat. 2025 May 18. doi: 10.1007/s10549-025-07723. PubMedAbstract available
ARRATO NA, Soo MS, Wren AA, Stalls JM, et al Impact of loving-kindness meditation intervention vs. music intervention during
biopsy on adherence to recommended breast cancer screening.
Breast Cancer Res Treat. 2025 May 16. doi: 10.1007/s10549-025-07721. PubMedAbstract available
HADIDCHI R, Duong KS, Hou J, Maldjian T, et al COVID-19 pandemic interruption of breast cancer screening is linked to clinical
upstaging at presentation: the roles of demographics, socioeconomic status and
unmet social needs.
Breast Cancer Res Treat. 2025 May 15. doi: 10.1007/s10549-025-07713. PubMedAbstract available
BECK AS, Earley M, Troxell M, Tsai J, et al Duration and effect of neoadjuvant endocrine therapy on invasive tumor
cellularity in hormone receptor-positive breast cancer.
Breast Cancer Res Treat. 2025 May 15. doi: 10.1007/s10549-025-07722. PubMedAbstract available
AJJAWI I, Rios A, Wei W, Park TS, et al Clinical, sociodemographic, and facility-related determinants of immunotherapy
use in metastatic triple-negative breast cancer.
Breast Cancer Res Treat. 2025 May 15. doi: 10.1007/s10549-025-07725. PubMedAbstract available
WOOLPERT KM, Ahern TP, Baurley JW, Maliniak ML, et al Genetic variants in tamoxifen metabolism and early treatment discontinuation
among premenopausal breast cancer patients.
Breast Cancer Res Treat. 2025 May 14. doi: 10.1007/s10549-025-07719. PubMedAbstract available
WOOSTER M, Chen L, Accordino MK, Sathe C, et al Utilization of weight management treatment and subsequent cardiovascular events
among patients with breast cancer.
Breast Cancer Res Treat. 2025 May 13. doi: 10.1007/s10549-025-07714. PubMedAbstract available
IWAI C, Miyawaki A, Konishi T, Okada A, et al Ocular adverse events of perioperative adjuvant docetaxel vs paclitaxel for
breast cancer: propensity-score overlap-weighted analysis.
Breast Cancer Res Treat. 2025 May 13. doi: 10.1007/s10549-025-07720. PubMedAbstract available
RADWAN RM, Schuster ALR, Hertz DL, Lustberg MB, et al Tolerance for chemotherapy-induced peripheral neuropathy among women with
metastatic breast cancer: a discrete-choice experiment.
Breast Cancer Res Treat. 2025 May 13. doi: 10.1007/s10549-025-07715. PubMedAbstract available
HEGER PW, Hotz D, Kalder M, Kostev K, et al Association between Extract Rheum rhaponticum 731 (ERr 731) prescription and
subsequent breast cancer.
Breast Cancer Res Treat. 2025 May 13. doi: 10.1007/s10549-025-07711. PubMedAbstract available
KOOIJMAN MML, Hage JJ, Scholten AN, van Duijnhoven FH, et al Advantages of immediate implant-based breast reconstruction over delayed breast
reconstruction in women treated with postmastectomy radiotherapy for breast
cancer.
Breast Cancer Res Treat. 2025 May 12. doi: 10.1007/s10549-025-07690. PubMedAbstract available
JANKOWSKI C, Houvenaeghel G, Renaudeau C, Leveque J, et al How can we optimize the surgical management of the axilla in breast cancer since
the MonarchE trial?
Breast Cancer Res Treat. 2025 May 6. doi: 10.1007/s10549-025-07642. PubMedAbstract available
GULTEKIN SC, Karadibak D, Cakir AB, Guc ZG, et al Self-administered versus lymphedema therapist-administered complex decongestive
therapy protocol in breast cancer-related lymphedema: a non-inferiority
randomized controlled trial with three-month follow-up.
Breast Cancer Res Treat. 2025 May 6. doi: 10.1007/s10549-025-07709. PubMedAbstract available
2024 RISE UP for breast cancer abstract collection.
Breast Cancer Res Treat. 2025 May 6. doi: 10.1007/s10549-025-07692. PubMed
LEE SF, Wong HCY, Robijns J, Ciocon SLB, et al Chronic skin toxicities in breast cancer survivors: a systematic review and
meta-analysis of radiotherapy techniques.
Breast Cancer Res Treat. 2025 May 5. doi: 10.1007/s10549-025-07700. PubMedAbstract available
WOCKEL A, Park-Simon TW, Korfel A, Raab K, et al Correction: Preferences of patients with high-risk HR+/HER2- breast cancer for
adjuvant endocrine treatment: an adaptive choice-based conjoint analysis study
from Germany.
Breast Cancer Res Treat. 2025;211:273-275. PubMed
OZEN A, Halici M Letter to the editor regarding the article "Comparison of survival between
unilateral and bilateral breast cancers using propensity score matching: a
retrospective single-center analysis".
Breast Cancer Res Treat. 2025;211:271-272. PubMedAbstract available
POELHEKKEN K, Dorrius MD, Dibden A, Duffy SW, et al The natural history of ductal carcinoma in situ: development, validation, and
estimated outcomes of the SimDCIS model.
Breast Cancer Res Treat. 2025;211:223-231. PubMedAbstract available
SAFGREN SL, Suman VJ, Leon Ferre RA, Kosel ML, et al The impact of coadministration of venlafaxine, citalopram or gabapentin on the
metabolic activation of tamoxifen.
Breast Cancer Res Treat. 2025;211:261-270. PubMedAbstract available
HEINDL F, Schiel J, Hack CC, Amann N, et al Malignant upgrade in lesions of uncertain malignant potential in the breast (B3
lesions) - is open excision always necessary?
Breast Cancer Res Treat. 2025;211:173-183. PubMedAbstract available
KHUBCHANDANI JA, Kc M, Dey P, Proussaloglou EM, et al Racial and ethnic disparities in conversion to mastectomy following lumpectomy.
Breast Cancer Res Treat. 2025;211:99-110. PubMedAbstract available
PADILLA DB, Tsai J, Beck AS, Wapnir IL, et al Lumpectomy surgery for large ductal carcinoma in situ.
Breast Cancer Res Treat. 2025;211:51-58. PubMedAbstract available
FRIEDEWALD SM, Sieniek M, Jansen S, Mahvar F, et al Triaging mammography with artificial intelligence: an implementation study.
Breast Cancer Res Treat. 2025;211:1-10. PubMedAbstract available
April 2025
MAURER C, Agostinetto E, Ameye L, Lambertini M, et al Association of statin use on survival outcomes of patients with early-stage
HER2-positive breast cancer in the APHINITY trial.
Breast Cancer Res Treat. 2025 Apr 28. doi: 10.1007/s10549-025-07699. PubMedAbstract available
SANVISENS A, Vidal-Vila A, Puigdemont M, Vinas G, et al Population-based analysis of breast cancer incidence and mortality: overall and
age-specific temporal trends over 40-year period in Girona, Spain.
Breast Cancer Res Treat. 2025 Apr 25. doi: 10.1007/s10549-025-07704. PubMedAbstract available
VIDULA N, Blouch E, Hesler K, Niemierko A, et al Brain metastases in patients with metastatic breast cancer and BRCA1/2 mutations
in cell-free DNA.
Breast Cancer Res Treat. 2025 Apr 25. doi: 10.1007/s10549-025-07705. PubMedAbstract available
WILKERSON AD, Obi M, Gentle C, Wei W, et al First mammogram-detected cancers portend worse survival in young women diagnosed
with breast cancer.
Breast Cancer Res Treat. 2025 Apr 25. doi: 10.1007/s10549-025-07703. PubMedAbstract available
FEST SN, Farland LV, Doody DR, Eliassen AH, et al Correction: Hormone-associated dietary patterns and premenopausal breast cancer
risk.
Breast Cancer Res Treat. 2025 Apr 24. doi: 10.1007/s10549-025-07706. PubMed
PERDRIX A, Olympios N, Rouvet J, Degremont M, et al Impact of pembrolizumab on ovarian function in young triple-negative breast
cancer patients treated with chemo-immunotherapy.
Breast Cancer Res Treat. 2025 Apr 22. doi: 10.1007/s10549-025-07702. PubMedAbstract available
ISIK B, Davey MG, Jaffer AA, Buckley J, et al Correction: Assessing the clinical utility of pre-operative neutrophil-lymphocyte
ratio as a predictor of clinicopathological parameters in patients being treated
for primary breast cancer.
Breast Cancer Res Treat. 2025 Apr 18. doi: 10.1007/s10549-025-07698. PubMed
GHOLAMI S, Saffarfar H, Mehraban MR, Ardabili NS, et al Targeting breast cancer: the promise of phage-based nanomedicines.
Breast Cancer Res Treat. 2025 Apr 17. doi: 10.1007/s10549-025-07696. PubMedAbstract available
LAU C, LaBorde K, Fatima B, Alfartosy SS, et al Non-adherence of cyclin-dependent kinases 4 and 6 inhibitors reduces overall and
progression-free survival in patients with hormone receptor-positive breast
cancer.
Breast Cancer Res Treat. 2025 Apr 16. doi: 10.1007/s10549-025-07701. PubMedAbstract available
SHIGEMATSU H, Takaya M, Suzuki K, Fujimoto M, et al Exploring the possibility of omitting axillary surgery in patients with clinical
node-positive breast cancer achieving ypT0 after neoadjuvant chemotherapy.
Breast Cancer Res Treat. 2025 Apr 12. doi: 10.1007/s10549-025-07697. PubMedAbstract available
MCQUEEN SRA, Chin WQ, Cunliffe HE, McDonald FJ, et al Stable overexpression of the epithelial sodium channel alpha subunit reduces
migration and proliferation in breast cancer cells.
Breast Cancer Res Treat. 2025 Apr 12. doi: 10.1007/s10549-025-07667. PubMedAbstract available
TURKOGLU E, Akdag Topal G, Yildirim S, Kinikoglu O, et al Comparison of paclitaxel and docetaxel in dual HER2 blockade: efficacy and safety
in neoadjuvant treatment of HER2-positive breast cancer.
Breast Cancer Res Treat. 2025 Apr 11. doi: 10.1007/s10549-025-07694. PubMedAbstract available
CHIEN YN, Lin LY, Lin YC, Hsieh YC, et al Correction: Taxane/anthracycline combinations reduced incidence of breast cancer
recurrence in young women across molecular subtypes: a real-world evidence of
Taiwan from 2011 to 2019.
Breast Cancer Res Treat. 2025 Apr 10. doi: 10.1007/s10549-025-07691. PubMed
DIAO B, Cai Y, Song D, Hu Y, et al A potential therapeutic molecule target: lncRNA AK023507 inhibits the metastasis
of breast cancer by regulating the WNT/DOCK4/beta-catenin axis.
Breast Cancer Res Treat. 2025 Apr 9. doi: 10.1007/s10549-025-07695. PubMedAbstract available
HIDAKA K, Goto-Yamaguchi L, Sueta A, Tomiguchi M, et al Identifying gene expression predictive of response to neoadjuvant endocrine
therapy in early breast cancer.
Breast Cancer Res Treat. 2025 Apr 9. doi: 10.1007/s10549-025-07693. PubMedAbstract available
JUNG W, Hubbard RA, Smith AM, Ko K, et al Risk-guided cardioprotection with carvedilol in patients with breast cancer (CCT
guide): a phase 1 randomized clinical trial.
Breast Cancer Res Treat. 2025 Apr 2. doi: 10.1007/s10549-025-07636. PubMedAbstract available
POTRONY M, Morales-Romero B, Moreno L, Pastor B, et al Considerations for hereditary breast and ovarian cancer syndrome molecular
diagnosis: experience from the clinical practice.
Breast Cancer Res Treat. 2025;210:507-519. PubMedAbstract available
MAKINELI S, Vriens MR, van Diest PJ, Witkamp AJ, et al Intraductal laser ablation during ductoscopy in patients with pathological nipple
discharge.
Breast Cancer Res Treat. 2025;210:329-335. PubMedAbstract available
CHEN Q, Elwood M, Campbell I, Cavadino A, et al Incidence trends of ductal carcinoma in situ in New Zealand women between 1999
and 2022.
Breast Cancer Res Treat. 2025;210:439-449. PubMedAbstract available
QIU ZX, Xie LY, Li YZ, Zhang ZC, et al L-ICG as an optical agent to improve intraoperative margin detection in
breast-conserving surgery: a prospective study.
Breast Cancer Res Treat. 2025;210:709-718. PubMedAbstract available
ERIN N, Tavsan E, Haksever S, Yerlikaya A, et al Targeting BMP-1 enhances anti-tumoral effects of doxorubicin in metastatic
mammary cancer: common and distinct features of TGF-beta inhibition.
Breast Cancer Res Treat. 2025;210:563-574. PubMedAbstract available
BAHL M, Kshirsagar A, Pohlman S, Lehman CD, et al Traditional versus modern approaches to screening mammography: a comparison of
computer-assisted detection for synthetic 2D mammography versus an artificial
intelligence algorithm for digital breast tomosynthesis.
Breast Cancer Res Treat. 2025;210:529-537. PubMedAbstract available
OZLER T, Cosar R, Sut N, Nurlu D, et al Comparison of survival between unilateral and bilateral breast cancers using
propensity score matching: a retrospective single-center analysis.
Breast Cancer Res Treat. 2025;210:673-686. PubMedAbstract available
STUTZ K, Mason H, Niakan S, Coulter AP, et al The impact of surgical technique on the number of sentinel lymph nodes removed
and its effect on complication rates.
Breast Cancer Res Treat. 2025;210:605-613. PubMedAbstract available
BAYRAM A, Bagbudar S, Karanlik H, Cabioglu N, et al Estrogen receptor positivity in stromal cells of the tumor bed predicts the
response to neoadjuvant chemotherapy for breast carcinoma.
Breast Cancer Res Treat. 2025;210:627-633. PubMedAbstract available
KORPINEN K, Autere TA, Tuominen J, Loyttyniemi E, et al Personalized multifactorial risk assessment in neoadjuvant-treated breast
carcinoma.
Breast Cancer Res Treat. 2025;210:463-475. PubMedAbstract available
QI M, Gao S, Zhang Z, Lang R, et al Secretory breast carcinoma: a multicenter clinicopathologic study of 80 cases
with emphasis on prognostic analysis and chemotherapy benefit.
Breast Cancer Res Treat. 2025;210:451-461. PubMedAbstract available
BERLANGA L, Lotersztein V, Aranda EI, Cerretini R, et al Contribution of large genomic rearrangements in BRCA1/2 genes and CHEK2 1100delC
allele variant to the development of breast/ovarian cancer in Argentinian
population.
Breast Cancer Res Treat. 2025;210:385-391. PubMedAbstract available
SUMAN L, D'Ascoli E, Depretto C, Berenghi A, et al Diagnostic performance of MRI-guided vacuum-assisted breast biopsy (VABB): an
essential but still underused technique.
Breast Cancer Res Treat. 2025;210:417-423. PubMedAbstract available
AL HASAN SM, Matthew KA, Toriola AT Education and mammographic breast density.
Breast Cancer Res Treat. 2025;210:377-384. PubMedAbstract available
TARIQ N, Dani S, Makhija P, Warren MV, et al Breast hamartomas associated with epithelial atypia and malignancy: are there
specific clinical, radiological or pathological features that identify at risk
patients?
Breast Cancer Res Treat. 2025;210:393-404. PubMedAbstract available
YOON KH, Ahn SH, Shin HC, Koh HW, et al Oncoplastic breast reconstruction with single-port laparoscopically harvested
omental flap: insights from a ten-year tertiary center experience.
Breast Cancer Res Treat. 2025;210:355-364. PubMedAbstract available
ZAMBRANO-O YT, Mejia-Garcia A, Morales PD, Tsao HM, et al Inference of genetic ancestry from a multi-gene cancer panel in Colombian women
with cancer.
Breast Cancer Res Treat. 2025;210:251-259. PubMedAbstract available
March 2025
FEST SN, Farland LV, Doody DR, Eliassen AH, et al Hormone-associated dietary patterns and premenopausal breast cancer risk.
Breast Cancer Res Treat. 2025 Mar 30. doi: 10.1007/s10549-025-07689. PubMedAbstract available
BRAUN M, Hamann M, Hanusch C, Andrulat A, et al Evaluating the impact of histological vs. nuclear grading on CPS + EG Score for
HR + /HER2-early breast cancer.
Breast Cancer Res Treat. 2025 Mar 28. doi: 10.1007/s10549-025-07685. PubMedAbstract available
NIKSERESHT S, Shewell LK, Day CJ, Jennings MP, et al Improved breast cancer diagnosis using a CA15-3 capture antibody-lectin sandwich
assay.
Breast Cancer Res Treat. 2025 Mar 27. doi: 10.1007/s10549-025-07672. PubMedAbstract available
ZHANG W, Shi S, Hong Y Comment on ''patient preferences for CDK4/6 inhibitor treatments in HR + /HER2-
early breast cancer: a discrete choice survey study''.
Breast Cancer Res Treat. 2025 Mar 27. doi: 10.1007/s10549-025-07673. PubMed
SUTTON AL, Zhao J, He J, Tossas KY, et al Examining factors associated with experiencing cardiac arrhythmias in Black and
White breast cancer survivors who received anthracyclines or trastuzumab.
Breast Cancer Res Treat. 2025 Mar 27. doi: 10.1007/s10549-025-07671. PubMedAbstract available
SHINN E, Zahrieh D, DeMichele A, Zdenkowski N, et al Impact of adding palbociclib on treatment adherence to ongoing adjuvant endocrine
treatment in the global randomized PALLAS randomized trial in patients with early
breast cancer.
Breast Cancer Res Treat. 2025 Mar 27. doi: 10.1007/s10549-025-07653. PubMedAbstract available
MODI S, Zhang S, Byng D, Hunter S, et al Treatment patterns and outcomes in HER2-low metastatic breast cancer patients
previously treated with chemotherapy: a US real-world cohort study.
Breast Cancer Res Treat. 2025 Mar 25. doi: 10.1007/s10549-025-07649. PubMedAbstract available
SCHONBERG MA, Wolfson EA, Eliassen AH, Rosner BA, et al Population attributable risk of a competing-risk model for breast cancer and
non-breast cancer death among women >/= 65 years.
Breast Cancer Res Treat. 2025 Mar 25. doi: 10.1007/s10549-025-07683. PubMedAbstract available
VENKATARAMAN J, Mokbel K Critical appraisal of a data mining model for predicting nodal response to
neoadjuvant treatment in breast cancer.
Breast Cancer Res Treat. 2025 Mar 21. doi: 10.1007/s10549-025-07686. PubMed
LIU H, Kou F, Hu L, Sun J, et al Potential candidates for adjuvant olaparib treatment in operable breast cancer
patients with germline BRCA1/2 pathogenic variants after neoadjuvant
chemotherapy.
Breast Cancer Res Treat. 2025 Mar 19. doi: 10.1007/s10549-025-07687. PubMedAbstract available
WANG J, Katsaros D, Wang Z, Ma L, et al Mitochondrial tRNA fragment, mt-tRF-Tyr-GTA-001 (tRF-21-X3OJI8EWB), in breast
cancer and its potential clinical implications.
Breast Cancer Res Treat. 2025 Mar 18. doi: 10.1007/s10549-025-07682. PubMedAbstract available
KRONEN EA, Chervu NL, Ng AP, Lee H, et al National trends and survival outcomes associated with non-guideline-concordant
treatment of inflammatory breast cancer.
Breast Cancer Res Treat. 2025 Mar 18. doi: 10.1007/s10549-025-07669. PubMedAbstract available
GAO Y, Zhang X, Ding M, Fu Z, et al Targeting "don't eat me" signal: breast cancer immunotherapy.
Breast Cancer Res Treat. 2025 Mar 18. doi: 10.1007/s10549-025-07659. PubMedAbstract available
AHN JH, Lee SJ, Yang SH, Kim JY, et al Clinical treatment score post-5 years and survival benefit from extended
endocrine therapy for breast cancer patients under and over 50 years of age.
Breast Cancer Res Treat. 2025 Mar 17. doi: 10.1007/s10549-025-07679. PubMedAbstract available
XIE LX, Liu Y, Yang YG, Wang JN, et al Postoperative radiotherapy improves long-term survival in HER2-positive
metastatic breast cancer: real-world evidence from the latest SEER database.
Breast Cancer Res Treat. 2025 Mar 14. doi: 10.1007/s10549-025-07665. PubMedAbstract available
GHORBANI M, Namazi S, Dehghani M, Razi F, et al Identifying the potential mediators of pathological complete response to
neoadjuvant chemotherapy among TACR1 gene polymorphisms: a study on breast cancer
patients.
Breast Cancer Res Treat. 2025 Mar 13. doi: 10.1007/s10549-025-07674. PubMedAbstract available
BASMADJIAN RB, Xu Y, Quan ML, Lupichuk S, et al Evaluating PREDICT and developing outcome prediction models in early-onset breast
cancer using data from Alberta, Canada.
Breast Cancer Res Treat. 2025 Mar 12. doi: 10.1007/s10549-025-07654. PubMedAbstract available
DE VIS JB, Wang C, Nguyen KV, Sun L, et al Body composition as a potential biomarker of recurrence risk in patients with
triple-negative breast cancer.
Breast Cancer Res Treat. 2025 Mar 11. doi: 10.1007/s10549-025-07675. PubMedAbstract available
BELLINI A, Keegan THM, Li Q, Jacinto A, et al The effect of body mass index on breast cancer stage and breast cancer specific
survival.
Breast Cancer Res Treat. 2025 Mar 10. doi: 10.1007/s10549-025-07678. PubMedAbstract available
ZHAN H, Antony VM, Tang H, Theriot J, et al PTEN inactivating mutations are associated with hormone receptor loss during
breast cancer recurrence.
Breast Cancer Res Treat. 2025 Mar 10. doi: 10.1007/s10549-025-07660. PubMedAbstract available
LI L, Zhang Z, Huang N, Ren J, et al IGF1R activates FOXP3-beta-catenin signaling to promote breast cancer development.
Breast Cancer Res Treat. 2025 Mar 7. doi: 10.1007/s10549-025-07663. PubMedAbstract available
NAKAUCHI C, Masunaga N, Kagara N, Oshiro C, et al Development of a prediction model for ctDNA detection (Cir-Predict) in breast
cancer.
Breast Cancer Res Treat. 2025 Mar 7. doi: 10.1007/s10549-025-07647. PubMedAbstract available
MCCANN KE, Osman N, Cannon J, Brent L, et al Goserelin 3-month depot shows non-inferiority to the monthly formulation in U.S.
patients with premenopausal breast cancer: a real-world evidence study.
Breast Cancer Res Treat. 2025 Mar 6. doi: 10.1007/s10549-025-07656. PubMedAbstract available
JUNG W, Park SH, Park YM, Song YM, et al Correction: Weight change and cardiovascular disease incidence in breast cancer
survivors: a nationwide cohort study.
Breast Cancer Res Treat. 2025 Mar 6. doi: 10.1007/s10549-025-07655. PubMed
'T HART D, Marriott R, Stone J Perceptions of breast cancer risk after breast density notification in a
population-based screening program.
Breast Cancer Res Treat. 2025 Mar 6. doi: 10.1007/s10549-025-07662. PubMedAbstract available
BERNSTEIN-MOLHO R, Haisraely O, Galper S, Abu-Shhada N, et al The impact of loco-regional treatment on ipsilateral breast cancer recurrence and
outcomes in carriers of BRCA1/2 pathogenic variants.
Breast Cancer Res Treat. 2025 Mar 5. doi: 10.1007/s10549-025-07658. PubMedAbstract available
BRABENDER D, Hossino D, Kim S, Jayich M, et al Factors associated with locoregional recurrence after neoadjuvant chemotherapy
for breast cancer in a safety-net medical center.
Breast Cancer Res Treat. 2025 Mar 4. doi: 10.1007/s10549-025-07668. PubMedAbstract available
HARDY ABELOOS C, Gurewitz J, Xiao J, Darvishian F, et al Is the risk of local recurrence higher for microinvasive breast cancer vs. early
stage invasive breast cancer?
Breast Cancer Res Treat. 2025 Mar 3. doi: 10.1007/s10549-025-07664. PubMedAbstract available
February 2025
KIM SH, Park GE, Bertrand KA, Sandler DP, et al Mammographic density as a predictor of invasive breast cancer and ductal
carcinoma in situ in over six million South Korean women.
Breast Cancer Res Treat. 2025 Feb 28. doi: 10.1007/s10549-025-07648. PubMedAbstract available
SULLIVAN M, Lei X, Karuturi M, Malinowski C, et al Use of adjuvant capecitabine in older patients with early-stage triple-negative
breast cancer.
Breast Cancer Res Treat. 2025 Feb 28. doi: 10.1007/s10549-025-07637. PubMedAbstract available
TERVASMAKI A, Kumpula TA, Grip M, Koivuluoma S, et al Population-based study of recurrent DNA damage response gene variants in breast
cancer cases.
Breast Cancer Res Treat. 2025 Feb 26. doi: 10.1007/s10549-025-07634. PubMedAbstract available
CHANDEKAR KR, Satapathy S, Dharmashaktu Y, Ballal S, et al Somatostatin receptor-targeted theranostics in patients with estrogen
receptor-positive metastatic breast cancer-a prospective exploratory study.
Breast Cancer Res Treat. 2025 Feb 26. doi: 10.1007/s10549-025-07651. PubMedAbstract available
RANDALL ARMEL S, Malcolmson J, Volenik A, Maganti M, et al Genetic counseling referral rates and genetic testing outcomes in women with
young breast cancer: a 20-year Canadian review.
Breast Cancer Res Treat. 2025 Feb 22. doi: 10.1007/s10549-025-07646. PubMedAbstract available
KIMURA T, Takami T, Piao Y, Wang M, et al Treatment patterns and clinical outcomes in patients with hormone
receptor-positive and human epidermal growth factor receptor 2-negative
metastatic breast cancer treated with chemotherapy: a large-scale data analysis
using the Japanese claims databas
Breast Cancer Res Treat. 2025 Feb 20. doi: 10.1007/s10549-025-07640. PubMedAbstract available
BANYS-PALUCHOWSKI M, Hartmann S, Basali T, Gasparri ML, et al Radar reflectors for marking of target lymph nodes in initially node-positive
patients receiving neoadjuvant chemotherapy for breast cancer-a subgroup analysis
of the prospective AXSANA (EUBREAST-03) trial.
Breast Cancer Res Treat. 2025 Feb 20. doi: 10.1007/s10549-025-07635. PubMedAbstract available
DING X, Wang Q, Kan H, Zhao F, et al The regulation mechanism of perceived stress on cognitive function of patients
with breast cancer undergoing chemotherapy: a multiple mediation analysis.
Breast Cancer Res Treat. 2025 Feb 20. doi: 10.1007/s10549-025-07641. PubMedAbstract available
WOCKEL A, Park-Simon TW, Korfel A, Raab K, et al Preferences of patients with high-risk HR + /HER2- breast cancer for adjuvant
endocrine treatment: an adaptive choice-based conjoint analysis study from
Germany.
Breast Cancer Res Treat. 2025 Feb 20. doi: 10.1007/s10549-025-07622. PubMedAbstract available
REAM M, Plotke R, Taub CJ, Borowsky PA, et al Cognitive behavioral stress management effects on cancer-related distress and
neuroendocrine signaling in breast cancer: differential effects by neighborhood
disadvantage.
Breast Cancer Res Treat. 2025 Feb 18. doi: 10.1007/s10549-025-07631. PubMedAbstract available
DESAI R, Jain A Long-term benefits of exercise interventions during chemotherapy in breast
cancer: insights from the optitrain trial calling for longitudinal studies.
Breast Cancer Res Treat. 2025 Feb 17. doi: 10.1007/s10549-025-07638. PubMed
HOLZEL D, Schlesinger-Raab A, Schubert-Fritschle G, Halfter K, et al Prolonged time to breast cancer surgery and the risk of metastasis: an
explorative simulation analysis using epidemiological data from Germany and the
USA.
Breast Cancer Res Treat. 2025 Feb 17. doi: 10.1007/s10549-025-07630. PubMedAbstract available
HUANG Z, Liu Y, Li S, Li Y, et al IHC4 and COMBINE scores for enhanced prognostic stratification in HR+/HER2-
breast cancer patients after neoadjuvant chemotherapy.
Breast Cancer Res Treat. 2025 Feb 15. doi: 10.1007/s10549-025-07645. PubMedAbstract available
ALBESHAN SM, Almuqbil MM, Elsharkawi MM, Nassri H, et al Outcomes of the Saudi breast cancer early detection program: a nine-year analysis
(2012-2020).
Breast Cancer Res Treat. 2025 Feb 14. doi: 10.1007/s10549-025-07633. PubMedAbstract available
DAI YW, Wu ZX, Cheng Y, Wu HD, et al Formosanin C inhibits triple-negative breast cancer progression by suppressing
the phosphorylation of STAT3 and the polarization of M2 macrophages.
Breast Cancer Res Treat. 2025 Feb 14. doi: 10.1007/s10549-025-07623. PubMedAbstract available
SUBELACK J, Morant R, Blum M, Eichenberger A, et al Risk factors for interval breast cancer: insights from a decade of a mammography
screening program.
Breast Cancer Res Treat. 2025 Feb 12. doi: 10.1007/s10549-025-07619. PubMedAbstract available
FENG X, Deng Z, McCullough MS, May BJ, et al The impact of cardiovascular risk factors on cancer progression: a prospective
study in female breast cancer survivors.
Breast Cancer Res Treat. 2025 Feb 10. doi: 10.1007/s10549-025-07611. PubMedAbstract available
CHEN N, Matossian M, Saha P, Rampurwala M, et al A randomized phase II trial of nab-paclitaxel with or without mifepristone for
advanced triple-negative breast cancer.
Breast Cancer Res Treat. 2025 Feb 10. doi: 10.1007/s10549-025-07626. PubMedAbstract available
MAYER EL, Smith ML, Guerin A, Latremouille-Viau D, et al Patient preferences for CDK4/6 inhibitor treatments in HR+/HER2- early breast
cancer: a discrete choice survey study.
Breast Cancer Res Treat. 2025 Feb 7. doi: 10.1007/s10549-025-07627. PubMedAbstract available
JOGENDRAN M, Flemming JA, Djerboua M, Korzeniowski M, et al The association between cirrhosis and outcomes among female patients undergoing
surgery for breast cancer in Ontario: a population-based study.
Breast Cancer Res Treat. 2025 Feb 3. doi: 10.1007/s10549-025-07612. PubMedAbstract available
COOPER K, Nalbant G, Essat M, Harnan S, et al Gene expression profiling tests to guide adjuvant chemotherapy decisions in lymph
node-positive early breast cancer: a systematic review.
Breast Cancer Res Treat. 2025 Feb 3. doi: 10.1007/s10549-024-07596. PubMedAbstract available
JANSEN BAM, Bargon CA, Bouman MA, van der Molen DRM, et al Patient-reported outcomes after immediate and delayed DIEP-flap breast
reconstruction in the setting of post-mastectomy radiation therapy-results of the
multicenter UMBRELLA breast cancer cohort.
Breast Cancer Res Treat. 2025 Feb 3. doi: 10.1007/s10549-025-07613. PubMedAbstract available
BONADIO RC, Tavares MC, Balint FC, de Sousa IM, et al Pathologic complete response rates of patients with ER-low/HER2-negative breast
cancer treated with neoadjuvant pembrolizumab plus chemotherapy in the neo-real
study.
Breast Cancer Res Treat. 2025 Feb 3. doi: 10.1007/s10549-025-07628. PubMedAbstract available
PARK E, Peterson L, McKeon S, Fiala MA, et al Returning to work after breast cancer: a longitudinal analysis of employment and
financial hardship.
Breast Cancer Res Treat. 2025 Feb 2. doi: 10.1007/s10549-025-07624. PubMedAbstract available
HASHEMI MH, Moaiery H, Nikkhoo B, Zamani F, et al Molecular Dynamics of Breast Cancer Subtypes: The Role of FAM83H-AS1 Long
Non-coding RNA in Breast Cancer Metastasis.
Breast Cancer Res Treat. 2025 Feb 1. doi: 10.1007/s10549-024-07603. PubMedAbstract available
ERGAS IJ, Cheng RK, Roh JM, Kresovich JK, et al Diet quality and cardiometabolic health in breast cancer survivors: the Pathways
Study.
Breast Cancer Res Treat. 2025 Feb 1. doi: 10.1007/s10549-025-07629. PubMedAbstract available
NEUNER JM, Stolley M, Kamaraju S, Tiegs J, et al The association of distress and depression screening measures and other
electronic health record information with adjuvant endocrine therapy persistence.
Breast Cancer Res Treat. 2025;209:541-552. PubMedAbstract available
LONG R, Luo Y, Cao M, Cao K, et al Malignancy risk stratification prediction of BI-RADS 4B calcifications based on
contrast-enhanced mammographic features: a multicenter study.
Breast Cancer Res Treat. 2025;210:135-145. PubMedAbstract available
LEE CW, Shin HJ, Kim HJ, Baek S, et al Performance of high-resolution diffusion-weighted magnetic resonance imaging for
detecting clinically occult early breast cancers: a multi-reader study.
Breast Cancer Res Treat. 2025;210:71-86. PubMedAbstract available
SAKATANI T, Tsuda H, Yoshida M, Honma N, et al Current status and challenges in HER2 IHC assessment: scoring survey results in
Japan.
Breast Cancer Res Treat. 2025;210:27-36. PubMedAbstract available
KUO MC, Sims J, Solis OK, Meszoely IM, et al Disease recurrence in patients undergoing mastectomy for ductal carcinoma in
situ.
Breast Cancer Res Treat. 2025;209:675-679. PubMedAbstract available
CHIKARMANE SA, Gibson A, Chesebro AL, Giess CS, et al Frequency and outcomes of new or suspicious MRI findings on breast MRI for
patients on neoadjuvant therapy.
Breast Cancer Res Treat. 2025;209:521-531. PubMedAbstract available
January 2025
LIU G, Pan LZ, Chen J, Ma J, et al Unveiling the role of PANoptosis-related genes in breast cancer: an integrated
study by multi-omics analysis and machine learning algorithms.
Breast Cancer Res Treat. 2025 Jan 28. doi: 10.1007/s10549-025-07620. PubMedAbstract available
STEARNS V, Chen R, Blackford AL, Saylor E, et al The Johns Hopkins Hope at Hopkins Clinic: supporting the comprehensive needs of
individuals with metastatic breast cancer.
Breast Cancer Res Treat. 2025 Jan 27. doi: 10.1007/s10549-024-07591. PubMedAbstract available
FEFFERMAN ML, Chan K, Cotler J, Thompson DM, et al Did the COVID-19 consortium recommendations impact the treatment of breast cancer
during the COVID-19 pandemic?
Breast Cancer Res Treat. 2025 Jan 26. doi: 10.1007/s10549-025-07617. PubMedAbstract available
DOYLE C, Lohmann AE, Iqbal N, Henning JW, et al A Canadian real-world, multi-center, prospective, observational study assessing
the treatment duration, the treatment sequence, and the overall survival for
patients treated with endocrine therapy +/- targeted therapy in HR + HER2-negative
advanced br
Breast Cancer Res Treat. 2025 Jan 23. doi: 10.1007/s10549-024-07580. PubMedAbstract available
KAI C, Tamori H, Ohtsuka T, Nara M, et al Classifying the molecular subtype of breast cancer using vision transformer and
convolutional neural network features.
Breast Cancer Res Treat. 2025 Jan 22. doi: 10.1007/s10549-025-07614. PubMedAbstract available
WILLIAMSON J, Kelley K, Scholand MB, Crossno C, et al Efficacy of a novel interstitial lung disease monitoring program in breast cancer
patients undergoing treatment with trastuzumab-deruxtecan.
Breast Cancer Res Treat. 2025 Jan 22. doi: 10.1007/s10549-024-07586. PubMedAbstract available
ISIK B, Davey MG, Jaffer AA, Buckley J, et al Assessing the clinical utility of pre-operative neutrophil-lymphocyte ratio as a
predictor of clinicopathological parameters in patients being treated for primary
breast cancer.
Breast Cancer Res Treat. 2025 Jan 20. doi: 10.1007/s10549-025-07615. PubMedAbstract available
ROHAN TE, Wang Y, Couch F, Feigelson HS, et al Clinicopathologic characteristics of ductal carcinoma in situ and risk of
subsequent invasive breast cancer: a multicenter, population-based cohort study.
Breast Cancer Res Treat. 2025 Jan 20. doi: 10.1007/s10549-024-07599. PubMedAbstract available
ASHOK KUMAR P, Sampat P, Sandhu M, Kumar VCS, et al A meta-analysis of the utility of cryotherapy for preventing peripheral
neuropathy among breast cancer patients receiving paclitaxel and nab-paclitaxel.
Breast Cancer Res Treat. 2025 Jan 19. doi: 10.1007/s10549-024-07597. PubMedAbstract available
BASHEY SZ, Kordon A, Ositelu K, Rao A, et al The role of statins in breast cancer survivors.
Breast Cancer Res Treat. 2025 Jan 16. doi: 10.1007/s10549-024-07605. PubMedAbstract available
BOGACZ P, Pelc Z, Mlak R, Sedlak K, et al Sentinel lymph node biopsy in breast cancer: the role of ICG fluorescence after
neoadjuvant chemotherapy.
Breast Cancer Res Treat. 2025 Jan 14. doi: 10.1007/s10549-025-07608. PubMedAbstract available
NYQVIST-STRENG J, Helou M, Helou K, Chamalidou C, et al The prognostic value of changes in Ki67 following neoadjuvant chemotherapy in
residual triple-negative breast cancer: a Swedish nationwide registry-based
study.
Breast Cancer Res Treat. 2025 Jan 12. doi: 10.1007/s10549-025-07610. PubMedAbstract available
MANIRUZZAMAN M, Bhuiyan MRH, Jaman MS, Haque MS, et al MicroRNA dynamics, PTEN/PI3K/AKT signaling, and their relationship to breast
cancer: prospects for pharmaceuticals and natural product application.
Breast Cancer Res Treat. 2025 Jan 10. doi: 10.1007/s10549-024-07600. PubMedAbstract available
GOKSEN TOSUN N, Kaplan O Dual targeting of HSP90 and BCL-2 in breast cancer cells using inhibitors BIIB021
and ABT-263.
Breast Cancer Res Treat. 2025 Jan 9. doi: 10.1007/s10549-024-07587. PubMedAbstract available
SCAFETTA R, Zagami P, Del Re M, Criscitiello C, et al Oral selective estrogen receptor degraders for breast cancer treatment: focus on
pharmacological differences.
Breast Cancer Res Treat. 2025 Jan 8. doi: 10.1007/s10549-024-07595. PubMedAbstract available
VICINI E, Galimberti V, Leonardi MC, Kahler-Ribeiro-Fontana S, et al Shifting from axillary dissection to targeted axillary surgery after neoadjuvant
treatment: the evolving management of occult breast cancer in a monoinstitutional
series of 114 patients.
Breast Cancer Res Treat. 2025 Jan 8. doi: 10.1007/s10549-024-07604. PubMedAbstract available
SILVA CR, Vieira DP, de Freitas AZ, Ribeiro MS, et al Photodynamic therapy as a strategic ally in radiotherapy for triple-negative
breast cancer: the importance of treatment order.
Breast Cancer Res Treat. 2025 Jan 8. doi: 10.1007/s10549-024-07607. PubMedAbstract available
OSLER TS, Schoeman M, Pretorius WJS, Mathew CG, et al Application of genetic testing criteria for hereditary breast cancer in South
Africa.
Breast Cancer Res Treat. 2025 Jan 7. doi: 10.1007/s10549-024-07585. PubMedAbstract available
SANOBA SA, Thull DL, McAuliffe PF, Steiman JG, et al Correction: Timely cancer genetic counseling and testing for young women with
breast cancer: impact on surgical decision-making for contralateral risk-reducing
mastectomy.
Breast Cancer Res Treat. 2025 Jan 7. doi: 10.1007/s10549-024-07573. PubMed
PILEHVARI A, You W, Kimmick G, Bonilla G, et al Disparities in treatment delays among metastatic breast cancer patients: insights
from nationwide electronic health records, 2011-2022.
Breast Cancer Res Treat. 2025 Jan 7. doi: 10.1007/s10549-024-07593. PubMedAbstract available
KNOWLTON SE, Wardell AC, Bailey C, Connelly B, et al Assessment of the functional and health-related needs of patients with metastatic
breast cancer prior to initiation of cancer treatment.
Breast Cancer Res Treat. 2025 Jan 6. doi: 10.1007/s10549-024-07590. PubMedAbstract available
JUNG W, Park SH, Park YM, Song YM, et al Weight change and cardiovascular disease incidence in breast cancer survivors: a
nationwide cohort study.
Breast Cancer Res Treat. 2025 Jan 6. doi: 10.1007/s10549-024-07594. PubMedAbstract available
XU Y, Cai Q, Li J, Guo W, et al Frequency of somatic and germline variants of predisposition genes in young
Chinese women with breast cancer.
Breast Cancer Res Treat. 2025 Jan 5. doi: 10.1007/s10549-024-07602. PubMedAbstract available
MARK C, Pujara V, Boyle MK, Yuan Y, et al Demographic and clinical trends of young breast cancer patients from the national
cancer database: disproportionate effect on minority populations.
Breast Cancer Res Treat. 2025 Jan 5. doi: 10.1007/s10549-024-07588. PubMedAbstract available
AHMED GA, Baron DH, Agrawal A Oncologic and cosmetic outcomes of oncoplastic breast-conserving surgery after
neoadjuvant systemic therapy: systematic review and meta-analysis.
Breast Cancer Res Treat. 2025;209:229-252. PubMedAbstract available
LI JJX, Ng JKM, Hon NKY, See KW, et al Effects on lymph node size, staging and primary tumor histology on diagnostic
accuracy of axillary lymph node aspirate of breast cancers.
Breast Cancer Res Treat. 2025;209:15-20. PubMedAbstract available
SAMAHA M, Fellner A, Raque K, Kuritzky A, et al Magnetic lymphatic tracing for omission of sentinel lymph node biopsies in
mastectomy patients: a community cancer center experience.
Breast Cancer Res Treat. 2025;209:161-166. PubMedAbstract available
SITU J, Walker C, Jayathungage Don TD, Suami H, et al Discordance between peritumoral and subareolar injections for mapping sentinel
lymph nodes in the breast.
Breast Cancer Res Treat. 2025;209:283-290. PubMedAbstract available
ROSENBERGER LH, Thomas SM, Hieken TJ, Gallagher KK, et al Germline genetic mutations in a multi-center cohort of 248 phyllodes tumors.
Breast Cancer Res Treat. 2025;209:275-282. PubMedAbstract available
SHIN E, Kim HM, Koo JS CD68 positive and/or CD163 positive tumor-associated macrophages and PD-L1
expression in breast phyllodes tumor.
Breast Cancer Res Treat. 2025;209:261-273. PubMedAbstract available
December 2024
FALTINOVA M, Vehmanen L, Lyytinen H, Savolainen-Peltonen H, et al Effects of vaginal estrogen on serum estradiol during aromatase inhibitor therapy
in breast cancer patients with vulvovaginal atrophy: a prospective trial.
Breast Cancer Res Treat. 2024 Dec 27. doi: 10.1007/s10549-024-07564. PubMedAbstract available
MALON D, Molto C, Prasla S, Cuthbert D, et al Steatotic liver disease in metastatic breast cancer treated with endocrine
therapy and CDK4/6 inhibitor.
Breast Cancer Res Treat. 2024 Dec 25. doi: 10.1007/s10549-024-07578. PubMedAbstract available
LAMONT EB, Stein E, Tarantino P, Tolaney SM, et al Pooled clinical trial analyses evaluating outcomes of HER2-low vs HER2-0
expression in patients with metastatic breast cancer following chemotherapy.
Breast Cancer Res Treat. 2024 Dec 20. doi: 10.1007/s10549-024-07581. PubMedAbstract available
LEGGAT-BARR K, Yee D, Duralde E, Hodge C, et al Correction: A roadmap to reduce the incidence and mortality of breast cancer by
rethinking our approach to women's health.
Breast Cancer Res Treat. 2024 Dec 20. doi: 10.1007/s10549-024-07572. PubMed
YUE M, Zhao J, Wu S, Cai L, et al Establishment of multiple machine learning prognostic model for gene differences
between primary tumors and lymph nodes in luminal breast cancer.
Breast Cancer Res Treat. 2024 Dec 10. doi: 10.1007/s10549-024-07574. PubMedAbstract available
SIGURJONSDOTTIR G, De Marchi T, Ehinger A, Hartman J, et al Evaluation of alternative prognostic thresholds for SP142 and 22C3
immunohistochemical PD-L1 expression in triple-negative breast cancer: results
from a population-based cohort.
Breast Cancer Res Treat. 2024 Dec 10. doi: 10.1007/s10549-024-07561. PubMedAbstract available
KAPPOS EA, Fabi A, Halbeisen FS, Abu-Ghazaleh A, et al Vascularized lymph node transfer (VLNT) versus lymphaticovenous anastomosis (LVA)
for chronic breast cancer-related lymphedema (BCRL): a retrospective cohort study
of effectiveness over time.
Breast Cancer Res Treat. 2024 Dec 10. doi: 10.1007/s10549-024-07567. PubMedAbstract available
BHATTACHARYA M, Liu B, Kurian AW, Stevens J, et al Receipt of guideline-concordant care and survival among young adult women with
non-metastatic breast cancer.
Breast Cancer Res Treat. 2024 Dec 9. doi: 10.1007/s10549-024-07570. PubMedAbstract available
WU M, Huang Q, Zhang L, Liu Y, et al Apo10 and TKTL1 in blood macrophages as potential biomarkers for early diagnosis
of operable breast cancer.
Breast Cancer Res Treat. 2024 Dec 7. doi: 10.1007/s10549-024-07569. PubMedAbstract available
PRASATH V, Boutrid H, Wesolowski R, Abdel-Rasoul M, et al Phase II study of MEK inhibitor trametinib alone and in combination with AKT
inhibitor GSK2141795/uprosertib in patients with metastatic triple negative
breast cancer.
Breast Cancer Res Treat. 2024 Dec 7. doi: 10.1007/s10549-024-07551. PubMedAbstract available
DI LEONE A, Filippone A, Maggiore C, Rossi MM, et al The role of body composition in neurological and hematologic toxicity in a
retrospective analysis of 120 breast cancer patients undergoing neoadjuvant
chemotherapy: the COMBOTOX study.
Breast Cancer Res Treat. 2024 Dec 4. doi: 10.1007/s10549-024-07553. PubMedAbstract available
RUGO HS, Campbell M, Yau C, Jo Chien A, et al Pexidartinib and standard neoadjuvant therapy in the adaptively randomized I-SPY2
trial for early breast cancer.
Breast Cancer Res Treat. 2024 Dec 3. doi: 10.1007/s10549-024-07555. PubMedAbstract available
LEONE JP, Leone J, Hassett MJ, Freedman RA, et al Incidence, treatment patterns, and mortality for patients with breast cancer
during the first year of the COVID-19 pandemic: a population-based study.
Breast Cancer Res Treat. 2024 Dec 2. doi: 10.1007/s10549-024-07562. PubMedAbstract available
SCHRUP S, Hardway H, Vierkant RA, Winham SJ, et al Microcalcifications in benign breast biopsies: association with lesion type and
risk.
Breast Cancer Res Treat. 2024;208:543-551. PubMedAbstract available
BOWLES EJA, Ramin C, Vo JB, Feigelson HS, et al Endocrine therapy initiation among women diagnosed with ductal carcinoma in situ
from 2001 to 2018.
Breast Cancer Res Treat. 2024;208:577-587. PubMedAbstract available
FALADE IO, Switalla KM, Baxter ME, Quirarte A, et al Variation in surgical treatment by body mass index in patients with invasive
lobular carcinoma of the breast.
Breast Cancer Res Treat. 2024;208:569-575. PubMedAbstract available
BEYPINAR I, Demir H, Yaslikaya S, Koseci T, et al Efficacy of everolimus plus hormonal treatment after cyclin-dependent kinase
inhibitor; real-life experience, A TOG study.
Breast Cancer Res Treat. 2024;208:597-604. PubMedAbstract available
LAITMAN Y, Niskakoski A, Bernstein-Molho R, Koskinen L, et al Phenotypes of carriers of two mutated alleles in major cancer susceptibility
genes.
Breast Cancer Res Treat. 2024;208:589-595. PubMedAbstract available
KUO AM, Reingold RE, Ketosugbo KF, Pan A, et al Oral minoxidil for late alopecia in cancer survivors.
Breast Cancer Res Treat. 2024;208:491-499. PubMedAbstract available
SOLIS O, Addae J, Sweeting R, Meszoely I, et al Cost containment analysis of superparamagnetic iron oxide (SPIO) injection in
patients with ductal carcinoma in situ.
Breast Cancer Res Treat. 2024;208:565-568. PubMedAbstract available
November 2024
ROZENBLIT M, Qing T, Ye Y, Zhao H, et al Rare germline variants in cancer-relevant genes are associated with breast cancer
risk in young women with high-risk family history.
Breast Cancer Res Treat. 2024 Nov 27. doi: 10.1007/s10549-024-07560. PubMedAbstract available
ANAMPA JD, Alvarez Soto A, Bernal AM, Acuna-Villaorduna A, et al Racial disparities in treatment and outcomes between Hispanic and non-Hispanic
black women with triple-negative breast cancer.
Breast Cancer Res Treat. 2024 Nov 26. doi: 10.1007/s10549-024-07565. PubMedAbstract available
HANF D, Fasching P, Gass P, Matthias W Beckmann, et al Impact of CCND1 amplification on the prognosis of hormone receptor-positive,
HER2-negative breast cancer patients-correlation of clinical and pathological
markers.
Breast Cancer Res Treat. 2024 Nov 26. doi: 10.1007/s10549-024-07545. PubMedAbstract available
ROCQUE GB, Blum JL, Ji Y, Pluard T, et al Real-world quality-of-life of patients with HR+/HER2- advanced breast cancer
treated with palbociclib plus endocrine therapy: EORTC QLQ-C30 results from
POLARIS.
Breast Cancer Res Treat. 2024 Nov 25. doi: 10.1007/s10549-024-07524. PubMedAbstract available
LACZMANSKA I, Matkowski R, Supplitt S, Karpinski P, et al Correction: Alterations in the expression of homologous recombination repair
(HRR) genes in breast cancer tissues considering germline BRCA1/2 mutation
status.
Breast Cancer Res Treat. 2024 Nov 23. doi: 10.1007/s10549-024-07544. PubMed
MATOSSIAN MD, Shiang C, Dolcen DN, Dreyer M, et al High tumor glucocorticoid receptor expression in early-stage, triple-negative
breast cancer is associated with increased T-regulatory cell infiltration.
Breast Cancer Res Treat. 2024 Nov 23. doi: 10.1007/s10549-024-07515. PubMedAbstract available
LONNING PE, Nikolaienko O, Knappskog S Letter to the Editor in response to paper "BRCA1 promoter methylation in
triple-negative breast cancer......" by K Daster et al.
Breast Cancer Res Treat. 2024 Nov 22. doi: 10.1007/s10549-024-07563. PubMed
ZHAO H, Shen C, Laureano JJ, Lei X, et al Real-world neoadjuvant and adjuvant Trastuzumab-containing regimen patterns and
their association with survival among patients with operable HER2-positive breast
cancer from 2007 to 2021.
Breast Cancer Res Treat. 2024 Nov 22. doi: 10.1007/s10549-024-07552. PubMedAbstract available
REFAAT S, Al-Rashidi HE, El Azeem RAA, Nouh WE, et al The functional TNF-alpha(-308)G > a single-nucleotide polymorphism (rs1800629):
association with the predictive indices of breast cancer carcinogenesis.
Breast Cancer Res Treat. 2024 Nov 21. doi: 10.1007/s10549-024-07536. PubMedAbstract available
ENGEL J, Wieder V, Bauer M, Kaufhold S, et al Correction: Prognostic and predictive impact of NOTCH1 in early breast cancer.
Breast Cancer Res Treat. 2024 Nov 20. doi: 10.1007/s10549-024-07520. PubMed
VAIDYA R, Till C, Henry NL, Fisch MJ, et al Neighborhood socioeconomic deprivation and patient-reported outcomes in symptom
management trials for women with breast cancer.
Breast Cancer Res Treat. 2024 Nov 19. doi: 10.1007/s10549-024-07523. PubMedAbstract available
GOLDVASER H, Yerushalmi R, Mutai R, Kuchuk I, et al ER + HER2- early-stage breast cancer: association of HER2 expression, tumor
characteristics, and outcomes.
Breast Cancer Res Treat. 2024 Nov 19. doi: 10.1007/s10549-024-07549. PubMedAbstract available
BETTARIGA F, Taaffe DR, Crespo-Garcia C, Clay TD, et al Effects of resistance training vs high intensity interval training on body
composition, muscle strength, cardiorespiratory fitness, and quality of life in
survivors of breast cancer: a randomized trial.
Breast Cancer Res Treat. 2024 Nov 18. doi: 10.1007/s10549-024-07559. PubMedAbstract available
LEE AW, Solis C, Tubman S, Wells N, et al Factors associated with breast cancer detection method in California women: an
analysis of California Health Interview Survey data.
Breast Cancer Res Treat. 2024 Nov 16. doi: 10.1007/s10549-024-07534. PubMedAbstract available
KO G, Li Q, Liu N, Amir E, et al Impact of the COVID-19 pandemic on breast cancer surgeries in a Canadian
population.
Breast Cancer Res Treat. 2024 Nov 15. doi: 10.1007/s10549-024-07547. PubMedAbstract available
ONASANYA O, Rosenblatt P, dosReis S, Onukwugha E, et al Trajectories of antidepressant use after tamoxifen initiation among young and
middle-aged women with breast cancer.
Breast Cancer Res Treat. 2024 Nov 15. doi: 10.1007/s10549-024-07554. PubMedAbstract available
RELLA R, Belli P, Romanucci G, Bufi E, et al Association between mammographic breast density and outcome in patients with
unilateral invasive breast cancer receiving neoadjuvant chemotherapy.
Breast Cancer Res Treat. 2024 Nov 12. doi: 10.1007/s10549-024-07548. PubMedAbstract available
LEGGAT-BARR K, Yee D, Duralde E, Hodge C, et al A roadmap to reduce the incidence and mortality of breast cancer by rethinking
our approach to women's health.
Breast Cancer Res Treat. 2024 Nov 12. doi: 10.1007/s10549-024-07522. PubMedAbstract available
RIZK M, Mokbel K Enhancing surgical precision: active marker localization at the time of biopsy in
breast cancer management.
Breast Cancer Res Treat. 2024 Nov 12. doi: 10.1007/s10549-024-07550. PubMed
HO KL, Tu Y, Dibble KE, Visvanathan K, et al The food environment and postdiagnosis weight gain among Black women breast
cancer survivors in Maryland.
Breast Cancer Res Treat. 2024 Nov 10. doi: 10.1007/s10549-024-07543. PubMedAbstract available
KOMATSU N, Chishima T, Watanabe C, Taruno K, et al Correction: Development of a novel prediction model for carriage of BRCA1/2
pathogenic variant in Japanese patients with breast cancer based on Japanese
organization of hereditary breast and ovarian cancer registry data.
Breast Cancer Res Treat. 2024 Nov 9. doi: 10.1007/s10549-024-07521. PubMed
EE C, Singleton A, Elder E, Davis N, et al The experience of weight gain during and after breast cancer treatment: a
qualitative study.
Breast Cancer Res Treat. 2024 Nov 7. doi: 10.1007/s10549-024-07528. PubMedAbstract available
ALMEKINDERS CAM, Lin L, Beijnen JH, Sonke GS, et al Treatment sequences and survival outcomes in advanced HR + HER2- breast cancer
patients: a real-world cohort.
Breast Cancer Res Treat. 2024 Nov 7. doi: 10.1007/s10549-024-07542. PubMedAbstract available
PISLAR N, Gasljevic G, Matos E, Pilko G, et al Predicting nodal response to neoadjuvant treatment in breast cancer with core
biopsy biomarkers of tumor microenvironment using data mining.
Breast Cancer Res Treat. 2024 Nov 4. doi: 10.1007/s10549-024-07539. PubMedAbstract available
VADLAKONDA A, Chervu NL, Porter G, Sakowitz S, et al Racial disparities in presenting stage and surgical management among
octogenarians with breast cancer: a national cancer database analysis.
Breast Cancer Res Treat. 2024 Nov 4. doi: 10.1007/s10549-024-07531. PubMedAbstract available
XING N, Liu D, Chen L, Wang G, et al Quantitative analysis of pressure levels in manual lymphatic drainage across
stages of breast cancer-related lymphedema: implications for optimized treatment
protocols.
Breast Cancer Res Treat. 2024 Nov 4. doi: 10.1007/s10549-024-07540. PubMedAbstract available
CHIEN YN, Lin LY, Lin YC, Hsieh YC, et al Taxane/anthracycline combinations reduced incidence of breast cancer recurrence
in young women across molecular subtypes: a real-world evidence of Taiwan from
2011 to 2019.
Breast Cancer Res Treat. 2024 Nov 2. doi: 10.1007/s10549-024-07527. PubMedAbstract available
PASETTO CV, Aguiar FN, Peixoto MB, Doria MT, et al Evaluation of tumor infiltrating lymphocytes as a prognostic biomarker in
patients with ductal carcinoma in situ of the breast.
Breast Cancer Res Treat. 2024;208:9-18. PubMedAbstract available
BORREGO MR, Lu YS, Reyes-Cosmelli F, Park YH, et al SGLT2 inhibition improves PI3Kalpha inhibitor-induced hyperglycemia: findings from
preclinical animal models and from patients in the BYLieve and SOLAR-1 trials.
Breast Cancer Res Treat. 2024;208:111-121. PubMedAbstract available
BOURGEOIS P Letter to the BRCT editor.
Breast Cancer Res Treat. 2024;208:201. PubMed
PEIPINS LA, Dasari S, Viox MH, Rodriguez JL, et al Information needs persist after genetic counseling and testing for BRCA1/2 and
Lynch Syndrome.
Breast Cancer Res Treat. 2024;208:19-27. PubMedAbstract available
CHEN Q, Campbell I, Elwood M, Cavadino A, et al Outcomes from low-risk ductal carcinoma in situ: a systematic review and
meta-analysis.
Breast Cancer Res Treat. 2024;208:237-251. PubMedAbstract available
RAMPAL R, Jones SJ, Hartup S, Robertson C, et al Three and twelve-month analysis of the PROM-Q study: comparison of
patient-reported outcome measures using the BREAST-Q questionnaire in pre- vs.
sub-pectoral implant-based immediate breast reconstruction.
Breast Cancer Res Treat. 2024;208:275-282. PubMedAbstract available
KAIDAR-PERSON O, Faermann R, Polikar D, Cohen K, et al A BRILLIANT-BRCA study: residual breast tissue after mastectomy and
reconstruction.
Breast Cancer Res Treat. 2024;208:359-367. PubMedAbstract available
CHO Y, Park EK, Chang Y, Kwon MR, et al Concordant and discordant breast density patterns by different approaches for
assessing breast density and breast cancer risk.
Breast Cancer Res Treat. 2024 Nov 1. doi: 10.1007/s10549-024-07541. PubMedAbstract available
October 2024
TERRA L, Boekel NB, Hooning MH, Collee M, et al Cardiovascular disease risk after breast cancer treatment in patients with a
BRCA1/2 pathogenic variant.
Breast Cancer Res Treat. 2024 Oct 31. doi: 10.1007/s10549-024-07516. PubMedAbstract available
OZA S, Patil S, Sampathkumar Y, Gany F, et al Trends in exercise initiation and participation among employed breast cancer
survivors undergoing curative treatment.
Breast Cancer Res Treat. 2024 Oct 31. doi: 10.1007/s10549-024-07526. PubMedAbstract available
BOSCOLO BIELO L, Guerini Rocco E, Crimini E, Repetto M, et al Molecular tumor board in patients with metastatic breast cancer.
Breast Cancer Res Treat. 2024 Oct 30. doi: 10.1007/s10549-024-07535. PubMedAbstract available
VAZ-GONCALVES L, Protani MM, Saunus JM, Colditz GA, et al Continental differences in the association between excess body weight and
prognosis in triple-negative breast cancer: a meta-analysis.
Breast Cancer Res Treat. 2024 Oct 30. doi: 10.1007/s10549-024-07538. PubMedAbstract available
GONZALEZ-NUNEZ C, Mohar A, Reynoso-Noveron N, Alvarez-Gomez RM, et al Clinical characteristics of male patients with breast cancer in the Latino
population.
Breast Cancer Res Treat. 2024 Oct 29. doi: 10.1007/s10549-024-07525. PubMedAbstract available
TAYA M, Merenbakh-Lamin K, Zubkov A, Honig Z, et al Beyond endocrine resistance: estrogen receptor (ESR1) activating mutations
mediate chemotherapy resistance through the JNK/c-Jun MDR1 pathway in breast
cancer.
Breast Cancer Res Treat. 2024 Oct 29. doi: 10.1007/s10549-024-07507. PubMedAbstract available
PHUNG TH, Pham TT, Nguyen HT, Nguyen DT, et al Clinicopathological characteristics of mucinous breast cancer: a retrospective
analysis of a 6-years study from national cancer center in Vietnam.
Breast Cancer Res Treat. 2024 Oct 23. doi: 10.1007/s10549-024-07529. PubMedAbstract available
JAHANGIRI S, Abdan Z, Soroush A, Houshmand M, et al Strong association of single nucleotide polymorphisms in BRCA1, ATM, and CHEK2
with breast cancer susceptibility in a sub-population of Iranian women.
Breast Cancer Res Treat. 2024 Oct 22. doi: 10.1007/s10549-024-07503. PubMedAbstract available
WOLFRAM S, Herriman SA, Lipps DB Prevalence and mechanisms of subacromial impingement in breast cancer patients
after breast-conserving surgery and radiation therapy: a case-cohort study.
Breast Cancer Res Treat. 2024 Oct 21. doi: 10.1007/s10549-024-07514. PubMedAbstract available
ROSENBERG SM, Zheng Y, Santos K, Riley E, et al Patient-reported outcomes, and perceptions and knowledge about recurrence in
women with hormone receptor-positive breast cancer.
Breast Cancer Res Treat. 2024 Oct 21. doi: 10.1007/s10549-024-07510. PubMedAbstract available
STEARNS V, ONeill A, Schneider BP, Skaar TC, et al CYP2D6 activity in patients with metastatic breast cancer treated with single
agent tamoxifen: results from ECOG-ACRIN E3108.
Breast Cancer Res Treat. 2024 Oct 21. doi: 10.1007/s10549-024-07519. PubMedAbstract available
COTTU P, Cheeseman S, Hall P, Wockel A, et al Attrition between lines of therapy and real-world outcomes of patients with
HER2-positive metastatic breast cancer in Europe: a cohort study leveraging
electronic medical records.
Breast Cancer Res Treat. 2024 Oct 20. doi: 10.1007/s10549-024-07506. PubMedAbstract available
GARCIA-MURILLAS I, Cutts RJ, Walsh-Crestani G, Phillips E, et al Longitudinal monitoring of circulating tumor DNA to detect relapse early and
predict outcome in early breast cancer.
Breast Cancer Res Treat. 2024 Oct 18. doi: 10.1007/s10549-024-07508. PubMedAbstract available
TALEC H, Aube C, Guerin-Charbonnel C, Berge P, et al The use of a clip prior to neoadjuvant chemotherapy for breast cancer with
microcalcifications may not always be required.
Breast Cancer Res Treat. 2024 Oct 17. doi: 10.1007/s10549-024-07517. PubMedAbstract available
ITO M, Amari M, Sato A, Hikichi M, et al Impact of extended endocrine therapy for patients with risk factors for late
recurrence in estrogen receptor-positive, human epidermal growth factor receptor
2-negative breast cancer after 5 years of endocrine therapy.
Breast Cancer Res Treat. 2024 Oct 17. doi: 10.1007/s10549-024-07509. PubMedAbstract available
BRUNELLE CL, Serig A Is axillary web syndrome a risk factor for breast cancer-related lymphedema of
the upper extremity? A systematic review and meta-analysis.
Breast Cancer Res Treat. 2024 Oct 16. doi: 10.1007/s10549-024-07518. PubMedAbstract available
LAI SW Comment on "Association between prediabetes and breast cancer: a comprehensive
meta-analysis".
Breast Cancer Res Treat. 2024 Oct 15. doi: 10.1007/s10549-024-07505. PubMed
ISHIKAWA E, Watanabe T, Kihara T, Kuroiwa M, et al The cytokine profile correlates with less tumor-infiltrating lymphocytes in
luminal A breast cancer.
Breast Cancer Res Treat. 2024 Oct 14. doi: 10.1007/s10549-024-07492. PubMedAbstract available
LV Z, Wang TY, Bi Y, Li D, et al BAFF overexpression in triple-negative breast cancer promotes tumor growth by
inducing IL-10-secreting regulatory B cells that suppress anti-tumor T cell
responses.
Breast Cancer Res Treat. 2024 Oct 14. doi: 10.1007/s10549-024-07504. PubMedAbstract available
LABELLA M, Lile-King RE, Agala CB, Spanheimer PM, et al Trends in management and related outcomes for occult primary breast cancer.
Breast Cancer Res Treat. 2024 Oct 13. doi: 10.1007/s10549-024-07500. PubMedAbstract available
DE AMORIM ISS, Pinheiro D, da Silva Oliveira M, de Sousa Rodrigues MM, et al APX2009 sensitizes hypoxic breast cancer cells to doxorubicin by increasing its
accumulation and caspase-3/7-mediated apoptosis.
Breast Cancer Res Treat. 2024 Oct 13. doi: 10.1007/s10549-024-07512. PubMedAbstract available
DASTER K, Hench J, Diepenbruck M, Volkmann K, et al BRCA promoter methylation in triple-negative breast cancer is preserved in
xenograft models and represents a potential therapeutic marker for PARP
inhibitors.
Breast Cancer Res Treat. 2024 Oct 11. doi: 10.1007/s10549-024-07502. PubMedAbstract available
PACHUAU L, Lalremmawia H, Ralte L, Vanlalpeka J, et al Uncovering novel pathogenic variants and pathway mutations in triple-negative
breast cancer among the endogamous mizo tribe.
Breast Cancer Res Treat. 2024 Oct 9. doi: 10.1007/s10549-024-07501. PubMedAbstract available
RASHID NS, Lamba N, Catalano PJ, Bi WL, et al Intracranial outcomes following neurosurgical resection in patients with brain
metastases secondary to HER2-positive breast cancer versus other subtypes.
Breast Cancer Res Treat. 2024 Oct 5. doi: 10.1007/s10549-024-07493. PubMedAbstract available
BITSIE KR, Pearson TA, Kwan ML, Yaghjyan L, et al Race and ethnicity and self-reported racial/ethnic discrimination in breast
cancer patient interactions with providers in the Pathways Study.
Breast Cancer Res Treat. 2024 Oct 5. doi: 10.1007/s10549-024-07499. PubMedAbstract available
BROWNE IM, McLaughlin RA, Weadick CS, O'Sullivan S, et al Irish national real-world analysis of the clinical and economic impact of 21-gene
oncotype DX(R) testing in early-stage, 1-3 lymph node-positive, oestrogen
receptor-positive, HER2-negative, breast cancer.
Breast Cancer Res Treat. 2024 Oct 4. doi: 10.1007/s10549-024-07486. PubMedAbstract available
KOMATSU N, Chishima T, Watanabe C, Taruno K, et al Development of a novel prediction model for carriage of BRCA1/2 pathogenic
variant in Japanese patients with breast cancer based on Japanese organization of
hereditary breast and ovarian cancer registry data.
Breast Cancer Res Treat. 2024 Oct 2. doi: 10.1007/s10549-024-07485. PubMedAbstract available
KESSLER AJ, Patel R, Gallagher EJ, Sheng T, et al Monitoring of estradiol levels in premenopausal women receiving adjuvant
abemaciclib and ovarian function suppression.
Breast Cancer Res Treat. 2024;207:529-532. PubMedAbstract available
TOMITA S, Yoshitake T, Matsunaga N, de Kerckhove M, et al Patient-reported outcomes and quality of life after breast-conserving surgery,
mastectomy, and breast reconstruction assessed using the BREAST-Q questionnaire.
Breast Cancer Res Treat. 2024;207:641-648. PubMedAbstract available
RAJAN KK, Nijveldt JJ, Verheijen S, Siesling S, et al Adherence to guideline recommendations for follow-up in patients with DCIS at a
large teaching hospital in the Netherlands.
Breast Cancer Res Treat. 2024;207:633-640. PubMedAbstract available
FARIA JP, Assumpcao JG, de Oliveira Matos L, Soardi FC, et al Spectrum of germline pathogenic variants in Brazilian hereditary breast/ovarian
cancer cases.
Breast Cancer Res Treat. 2024;207:615-624. PubMedAbstract available
LEONARDIS JM, Momoh AO, Lipps DB Choosing breast-conserving therapy or mastectomy and subpectoral implant breast
reconstruction: implications for pectoralis major function.
Breast Cancer Res Treat. 2024;207:569-578. PubMedAbstract available
SOLEIMANI T, Euhus D, Sogunro O, Cope L, et al De-escalating indications for excision when breast core needle biopsy returns
fibroepithelial lesion-not further characterized.
Breast Cancer Res Treat. 2024;207:561-568. PubMedAbstract available
SANTANA VALENCIANO A, Rivas Fidalgo S, Corral Moreno S, Gamero Medina V, et al Surgical marker navigation system in breast conserving surgery and excision of
non-palpable lesions: first Spanish single-center experience.
Breast Cancer Res Treat. 2024;207:533-540. PubMedAbstract available
MARTINS-BRANCO D, Brandao M, de Azambuja E Response to letter "re: Surgery of the primary tumor in patients with de novo
metastatic breast cancer: A nationwide population-based retrospective cohort
study in Belgium and the National Cancer Database (NCDB)".
Breast Cancer Res Treat. 2024 Oct 1. doi: 10.1007/s10549-024-07498. PubMed
September 2024
VERRECK EEF, Kuijer A, van Steenhoven JEC, Volders JH, et al 70-Gene signature-guided adjuvant systemic treatment adjustments in early-stage
ER+ breast cancer patients: 7-year follow-up of a prospective multicenter cohort
study.
Breast Cancer Res Treat. 2024 Sep 30. doi: 10.1007/s10549-024-07496. PubMedAbstract available
WOJCIK KM, Wilson OWA, Kamil D, Rajagopal PS, et al Clinical and sociodemographic determinants of older breast cancer survivors'
reports of receiving advice about exercise.
Breast Cancer Res Treat. 2024 Sep 30. doi: 10.1007/s10549-024-07460. PubMedAbstract available
GUNSTER JLB, van Duijnhoven FH, Scholten AN, Smorenburg CH, et al The efficacy of screening with FDG-PET/CT for distant metastases in breast cancer
patients scheduled for neoadjuvant systemic therapy.
Breast Cancer Res Treat. 2024 Sep 26. doi: 10.1007/s10549-024-07478. PubMedAbstract available
KULIGINA ES, Romanko AA, Jankevic T, Martianov AS, et al HLA gene polymorphism is a modifier of age-related breast cancer penetrance in
carriers of BRCA1 pathogenic alleles.
Breast Cancer Res Treat. 2024 Sep 21. doi: 10.1007/s10549-024-07497. PubMedAbstract available
JACOB S, Christofferson A, Fisch S, Norwood P, et al Regional lymph node changes on breast MRI in patients with early-stage breast
cancer receiving neoadjuvant chemo-immunotherapy.
Breast Cancer Res Treat. 2024 Sep 21. doi: 10.1007/s10549-024-07481. PubMedAbstract available
BANSAL R, Adeyelu T, Elliott A, Walker P, et al Genomic and transcriptomic landscape of HER2-low breast cancer.
Breast Cancer Res Treat. 2024 Sep 20. doi: 10.1007/s10549-024-07495. PubMedAbstract available
SCHMIDT JA, Hjorth CF, Farkas DK, Damkier P, et al Genetic variants and social benefit receipt in premenopausal women with breast
cancer treated with docetaxel: a Danish population-based cohort study.
Breast Cancer Res Treat. 2024 Sep 20. doi: 10.1007/s10549-024-07474. PubMedAbstract available
JANSSEN LM, de Vries BBLP, Janse MHA, van der Wall E, et al Tumor infiltrating lymphocytes and change in tumor load on MRI to assess response
and prognosis after neoadjuvant chemotherapy in breast cancer.
Breast Cancer Res Treat. 2024 Sep 16. doi: 10.1007/s10549-024-07484. PubMedAbstract available
MIRZA L, Steventon L, Roylance R, Hughes C, et al Regional differences in neo/adjuvant chemotherapy timing in patients with
early-stage triple-negative breast cancer in England.
Breast Cancer Res Treat. 2024 Sep 16. doi: 10.1007/s10549-024-07480. PubMedAbstract available
THAI CHNC, An SJ, Haase CR, Selfridge JM, et al Differential prognostic value of residual nodal burden in breast cancer subtypes.
Breast Cancer Res Treat. 2024 Sep 15. doi: 10.1007/s10549-024-07494. PubMedAbstract available
HENNEGHAN AM, Van Dyk KM, Haywood D, Patel M, et al Characterizing cancer-related cognitive impairments and impact on quality of life
in women with metastatic breast cancer.
Breast Cancer Res Treat. 2024 Sep 13. doi: 10.1007/s10549-024-07479. PubMedAbstract available
ZHU HR, Wei YB, Guo JQ, Liu XF, et al Double-negative T cells with a distinct transcriptomic profile are abundant in
the peripheral blood of patients with breast cancer.
Breast Cancer Res Treat. 2024 Sep 10. doi: 10.1007/s10549-024-07477. PubMedAbstract available
NELSON RA, Chlebowski RT, Pan K, Rohan TE, et al Breast Cancer Risk Assessment Tool (BCRAT) and long-term breast cancer mortality
in the Women's Health Initiative.
Breast Cancer Res Treat. 2024 Sep 10. doi: 10.1007/s10549-024-07470. PubMedAbstract available
DUARTE BN, Alem CER, da Silva Cabello AER, Teixeira SRC, et al Risk-reducing surgeries for breast cancer in Brazilian patients undergoing
multigene germline panel: impact of results on decision making.
Breast Cancer Res Treat. 2024 Sep 10. doi: 10.1007/s10549-024-07476. PubMedAbstract available
SARTOR H, Hagberg O, Hemmingsson O, Lang K, et al Breast cancer recurrence in relation to mode of detection: implications on
personalized surveillance.
Breast Cancer Res Treat. 2024 Sep 10. doi: 10.1007/s10549-024-07475. PubMedAbstract available
GUO Q, Liu M, Li Y, Sun Q, et al Overcoming technical hurdles in mobile health: insights from the Fit2ThriveMB
breast cancer study.
Breast Cancer Res Treat. 2024 Sep 5. doi: 10.1007/s10549-024-07483. PubMed
TANG WZ, Deng WX, Liu TH Letter to the editor: "Frequency of zoledronate administration in early breast
cancer".
Breast Cancer Res Treat. 2024 Sep 4. doi: 10.1007/s10549-024-07490. PubMed
SWEDE H, Ridwan SM, Strandberg J, Salner AL, et al Baseline sLAG-3 levels in Caucasian and African-American breast cancer patients.
Breast Cancer Res Treat. 2024 Sep 4. doi: 10.1007/s10549-024-07455. PubMedAbstract available
August 2024
WALYELDEEN AA, Sabet S, Anis SE, Stein T, et al Correction: FBLN2 is associated with basal cell markers Krt14 and ITGB1 in mouse
mammary epithelial cells and has a preferential expression in molecular subtypes
of human breast cancer.
Breast Cancer Res Treat. 2024 Aug 29. doi: 10.1007/s10549-024-07472. PubMed
CONLEY CC, Anderson A, Rodriguez JD, Kang H, et al Barriers and facilitators to breast cancer screening among high-risk women: a
qualitative study.
Breast Cancer Res Treat. 2024 Aug 27. doi: 10.1007/s10549-024-07471. PubMedAbstract available
BRUFSKY A, Kwan ML, Sandin R, Stergiopoulos S, et al Trends in HR+ metastatic breast cancer survival before and after CDK4/6 inhibitor
introduction in the United States: a SEER registry analysis of patients with
HER2- and HER2+ metastatic breast cancer.
Breast Cancer Res Treat. 2024 Aug 23. doi: 10.1007/s10549-024-07469. PubMedAbstract available
GUNASEKHARAN V, Lin HK, Marczyk M, Rios-Hoyo A, et al Phosphoenolpyruvate carboxykinase-2 (PCK2) is a therapeutic target in
triple-negative breast cancer.
Breast Cancer Res Treat. 2024 Aug 23. doi: 10.1007/s10549-024-07462. PubMedAbstract available
DU X, Huang X, Feng X, Shui Y, et al The effects of the-optimal-lymph-flow health IT system application on
treatment-related high risk lymphedema in breast cancer patients: a randomized
controlled trial.
Breast Cancer Res Treat. 2024 Aug 23. doi: 10.1007/s10549-024-07468. PubMedAbstract available
SPENCER JV, Liu J, Deyarmin B, Hu H, et al Cytokine levels in breast cancer are highly dependent on cytomegalovirus (CMV)
status.
Breast Cancer Res Treat. 2024 Aug 22. doi: 10.1007/s10549-024-07459. PubMedAbstract available
WILLIS C, Tan CJ, Chhibber A, Watanabe AH, et al Patient characteristics and treatment patterns of patients with locally advanced
or metastatic HER2-low breast cancer, a single site descriptive study.
Breast Cancer Res Treat. 2024 Aug 22. doi: 10.1007/s10549-024-07458. PubMedAbstract available
FRANDSEN CLB, Nohr B, Gottschau M, Viuff JH, et al Polycystic ovary syndrome and risk of breast cancer in premenopausal and
postmenopausal women: a nationwide population-based cohort study.
Breast Cancer Res Treat. 2024 Aug 21. doi: 10.1007/s10549-024-07467. PubMedAbstract available
ENGEL J, Wieder V, Bauer M, Kaufhold S, et al Prognostic and predictive impact of NOTCH1 in early breast cancer.
Breast Cancer Res Treat. 2024 Aug 17. doi: 10.1007/s10549-024-07444. PubMedAbstract available
BLANTER J, Baldwin E, Patel R, Sheng T, et al Patterns in use and tolerance of adjuvant neratinib in patients with hormone
receptor (HR)-positive, HER2-positive early-stage breast cancer.
Breast Cancer Res Treat. 2024 Aug 17. doi: 10.1007/s10549-024-07461. PubMedAbstract available
BHIMANI J, O'Connell K, Persaud S, Blinder V, et al The landscape of use of NCCN-guideline chemotherapy regimens in stage I-IIIA
breast cancer in an integrated healthcare delivery system.
Breast Cancer Res Treat. 2024 Aug 16. doi: 10.1007/s10549-024-07433. PubMedAbstract available
MELINK Z, Lustberg MB, Schnell PM, Mezzanotte-Sharpe J, et al Effect of minocycline on changes in affective behaviors, cognitive function, and
inflammation in breast cancer survivors undergoing chemotherapy: a pilot
randomized controlled trial.
Breast Cancer Res Treat. 2024 Aug 14. doi: 10.1007/s10549-024-07457. PubMedAbstract available
KAUR M, Rothschild HT, Mukhtar RA Reply to: "Surgery of the primary tumor in patients with de novo metastatic
breast cancer: a nationwide population-based retrospective cohort study in
Belgium and the National Cancer Database (NCDB)".
Breast Cancer Res Treat. 2024 Aug 12. doi: 10.1007/s10549-024-07465. PubMed
LI Z, Ye X Integrating social work and shared decision-making for equity in metastatic
breast cancer care.
Breast Cancer Res Treat. 2024 Aug 10. doi: 10.1007/s10549-024-07463. PubMed
ALTUNDAG K Different distant breast cancer metastases might show discordant hormone receptor
status in the same patient.
Breast Cancer Res Treat. 2024 Aug 10. doi: 10.1007/s10549-024-07464. PubMed
ZENG F, Heng J, Guo X, Wang Y, et al Correction: The novel TP53 3'-end methylation pattern associated with its
expression would be a potential biomarker for breast cancer detection.
Breast Cancer Res Treat. 2024 Aug 8. doi: 10.1007/s10549-024-07424. PubMed
WONG HCY, Lee SF, Caini S, Chan AW, et al Barrier films or dressings for the prevention of acute radiation dermatitis in
breast cancer: a systematic review and network meta-analysis.
Breast Cancer Res Treat. 2024 Aug 7. doi: 10.1007/s10549-024-07435. PubMedAbstract available
WALYELDEEN AA, Sabet S, Anis SE, Stein T, et al FBLN2 is associated with basal cell markers Krt14 and ITGB1 in mouse mammary
epithelial cells and has a preferential expression in molecular subtypes of human
breast cancer.
Breast Cancer Res Treat. 2024 Aug 7. doi: 10.1007/s10549-024-07447. PubMedAbstract available
FREEMAN HD, Burke LC, Humphrey JG, Wilbers AJ, et al Fragmentation of care in breast cancer: greater than the sum of its parts.
Breast Cancer Res Treat. 2024 Aug 3. doi: 10.1007/s10549-024-07442. PubMedAbstract available
KINSEY-TROTMAN S, Nguyen A, Edwards S, Swalling A, et al Influence of tumour grade on disease survival in male breast cancer patients: a
systematic review.
Breast Cancer Res Treat. 2024 Aug 2. doi: 10.1007/s10549-024-07446. PubMedAbstract available
ROCQUE GB, Eltoum N, Caston NE, Williams CP, et al A randomized controlled trial of shared decision-making treatment planning
process to enhance shared decision-making in patients with MBC.
Breast Cancer Res Treat. 2024;206:483-493. PubMedAbstract available
SURMELI Z Letter to the editor: "Body composition measures as a determinant of
alpelisib-related toxicity".
Breast Cancer Res Treat. 2024;206:677. PubMed
ROCA NAVARRO MJ, Oliver Goldaracena JM, Garrido Alonso D, Navarro Monforte Y, et al Pre-surgical cryoablation in = 2 cm ER + /HER2-tumors. Prognostic factors for the
presence of residual invasive carcinoma.
Breast Cancer Res Treat. 2024;206:561-573. PubMedAbstract available
STEAD TS, Lu CY, Geletzke A, Butler E, et al Indocyanine green angiography guidance for vascular preservation in skin and
nipple sparing mastectomy.
Breast Cancer Res Treat. 2024;206:575-583. PubMedAbstract available
ANDERSON SA, Bartow BB, Harada S, Siegal GP, et al p53 protein expression patterns associated with TP53 mutations in breast
carcinoma.
Breast Cancer Res Treat. 2024;207:213-222. PubMedAbstract available
ZENG A, Houssami N, Noguchi N, Nickel B, et al Frequency and characteristics of errors by artificial intelligence (AI) in
reading screening mammography: a systematic review.
Breast Cancer Res Treat. 2024;207:1-13. PubMedAbstract available
PAN K, Nelson RA, Chlebowski RT, Piela R, et al Ductal carcinoma in situ and cause-specific mortality among younger and older
postmenopausal women: the Women's Health Initiative.
Breast Cancer Res Treat. 2024;207:65-79. PubMedAbstract available
THOMPSON CN, Chandler J, Ju T, Tsai J, et al Residual cancer burden in two-stage nipple sparing mastectomy after first stage
lumpectomy and devascularization of the nipple areolar complex.
Breast Cancer Res Treat. 2024;207:143-149. PubMedAbstract available
DOWLING GP, Keelan S, Cosgrove NS, Daly GR, et al Receptor Discordance in Metastatic Breast Cancer; a review of clinical and
genetic subtype alterations from primary to metastatic disease.
Breast Cancer Res Treat. 2024 Aug 1. doi: 10.1007/s10549-024-07431. PubMedAbstract available
July 2024
AWAN AA, Stober C, Pond GR, Machado I, et al A randomised trial comparing 6-monthly adjuvant zoledronate with a single
one-time dose in patients with early breast cancer.
Breast Cancer Res Treat. 2024 Jul 31. doi: 10.1007/s10549-024-07443. PubMedAbstract available
IZABELA L, Rafal M, Stanislaw S, Pawel K, et al Alterations in the expression of homologous recombination repair (HRR) genes in
breast cancer tissues considering germline BRCA1/2 mutation status.
Breast Cancer Res Treat. 2024 Jul 30. doi: 10.1007/s10549-024-07441. PubMedAbstract available
FANSA S, Ghusn W, Tama E, Nicolalde B, et al Efficacy of antiobesity medications among breast cancer survivors taking
aromatase inhibitors.
Breast Cancer Res Treat. 2024 Jul 30. doi: 10.1007/s10549-024-07450. PubMedAbstract available
MOKHTARPOUR K, Razi S, Rezaei N Correction: Ferroptosis as a promising targeted therapy for triple negative
breast cancer.
Breast Cancer Res Treat. 2024 Jul 30. doi: 10.1007/s10549-024-07438. PubMed
WANG Z, Lu Y, Han M, Li A, et al Association between homologous recombination deficiency status and carboplatin
treatment response in early triple-negative breast cancer.
Breast Cancer Res Treat. 2024 Jul 24. doi: 10.1007/s10549-024-07436. PubMedAbstract available
ZHOU K, Zhang M, Zhai D, Wang Z, et al Genomic and transcriptomic profiling of inflammatory breast cancer reveals
distinct molecular characteristics to non-inflammatory breast cancers.
Breast Cancer Res Treat. 2024 Jul 19. doi: 10.1007/s10549-024-07437. PubMedAbstract available
SATO T, Oshi M, Huang JL, Chida K, et al CD133 expression is associated with less DNA repair, better response to
chemotherapy and survival in ER-positive/HER2-negative breast cancer.
Breast Cancer Res Treat. 2024 Jul 17. doi: 10.1007/s10549-024-07434. PubMedAbstract available
PHILLIPS SM, Starikovsky J, Solk P, Desai R, et al Feasibility and preliminary effects of the Fit2ThriveMB pilot physical activity
promotion intervention on physical activity and patient reported outcomes in
individuals with metastatic breast cancer.
Breast Cancer Res Treat. 2024 Jul 16. doi: 10.1007/s10549-024-07432. PubMedAbstract available
BHAVE MA, Quintanilha JCF, Tukachinsky H, Li G, et al Correction: Comprehensive genomic profiling of ESR1, PIK3CA, AKT1, and PTEN in
HR(+)HER2(-) metastatic breast cancer: prevalence along treatment course and
predictive value for endocrine therapy resistance in real-world practice.
Breast Cancer Res Treat. 2024 Jul 13. doi: 10.1007/s10549-024-07427. PubMed
FOLDI J, Blenman KRM, Marczyk M, Gunasekharan V, et al Peripheral blood immune parameters, response, and adverse events after
neoadjuvant chemotherapy plus durvalumab in early-stage triple-negative breast
cancer.
Breast Cancer Res Treat. 2024 Jul 13. doi: 10.1007/s10549-024-07426. PubMedAbstract available
SANJAYA A, Ratnawati H, Adhika OA, Rahmatilah FR, et al The heterogeneity of breast cancer metastasis: a bioinformatics analysis
utilizing single-cell RNA sequencing data.
Breast Cancer Res Treat. 2024 Jul 11. doi: 10.1007/s10549-024-07428. PubMedAbstract available
DU KY, Wu S, Ma X, Liu Y, et al Circulating tumor cell phenotype detection based on epithelial-mesenchymal
transition markers combined with clinicopathological risk has potential to better
predict recurrence in stage III breast cancer treated with neoadjuvant
chemotherapy: a pilot s
Breast Cancer Res Treat. 2024 Jul 11. doi: 10.1007/s10549-024-07430. PubMedAbstract available
KUMAR S, Ziegler Y, Plotner BN, Flatt KM, et al Resistance to FOXM1 inhibitors in breast cancer is accompanied by impeding
ferroptosis and apoptotic cell death.
Breast Cancer Res Treat. 2024 Jul 9. doi: 10.1007/s10549-024-07420. PubMedAbstract available
LIANG E, Beshara M, Sheng H, Huang XW, et al A prospective study of vitamin D, proinflammatory cytokines, and risk of
fragility fractures in women on aromatase inhibitors for breast cancer.
Breast Cancer Res Treat. 2024 Jul 8. doi: 10.1007/s10549-024-07423. PubMedAbstract available
CHIDA K, Oshi M, Roy AM, Sato T, et al Enhanced cancer cell proliferation and aggressive phenotype counterbalance in
breast cancer with high BRCA1 gene expression.
Breast Cancer Res Treat. 2024 Jul 7. doi: 10.1007/s10549-024-07421. PubMedAbstract available
BRANTLEY KD, Tamimi RM The association between infectious agents and breast cancer: a review of the
epidemiologic evidence.
Breast Cancer Res Treat. 2024 Jul 6. doi: 10.1007/s10549-024-07388. PubMedAbstract available
MEZZANOTTE-SHARPE J, ONeill A, Mayer IA, Arteaga CL, et al A randomized phase III double-blind placebo-controlled trial of first-line
chemotherapy and trastuzumab with or without bevacizumab for patients with
HER2/neu-positive metastatic breast cancer: a trial of the ECOG-ACRIN Cancer
Research Group (E1105).
Breast Cancer Res Treat. 2024 Jul 5. doi: 10.1007/s10549-024-07417. PubMedAbstract available
CHEN HW, Kuo WH, Lu YS, Chen IC, et al Interaction of base excision repair gene polymorphism and estrogen-DNA adducts in
breast cancer risk among East Asian women.
Breast Cancer Res Treat. 2024 Jul 5. doi: 10.1007/s10549-024-07418. PubMedAbstract available
SIMMONS R, Kameyama H, Kubota S, Sun Y, et al Sustained delivery of celecoxib from nanoparticles embedded in hydrogel injected
into the biopsy cavity to prevent biopsy-induced breast cancer metastasis.
Breast Cancer Res Treat. 2024 Jul 5. doi: 10.1007/s10549-024-07410. PubMedAbstract available
FEFFERMAN ML, Stump TK, Thompson D, Simovic S, et al Patient-reported observations on medical procedure timeliness (PROMPT) in breast
cancer: a qualitative study.
Breast Cancer Res Treat. 2024 Jul 4. doi: 10.1007/s10549-024-07406. PubMedAbstract available
MAGNONI F, Bianchi B, Pagan E, Corso G, et al Long-term outcome of invasive pure micropapillary breast cancer compared with
invasive mixed micropapillary and invasive ductal breast cancer: a matched
retrospective study.
Breast Cancer Res Treat. 2024 Jul 4. doi: 10.1007/s10549-024-07422. PubMedAbstract available
MATHESON J, Elder K, Nickson C, Park A, et al Contrast-enhanced mammography for surveillance in women with a personal history
of breast cancer.
Breast Cancer Res Treat. 2024 Jul 4. doi: 10.1007/s10549-024-07419. PubMedAbstract available
FANG T, Hu S, Song X, Wang J, et al Combination of monensin and erlotinib synergistically inhibited the growth and
cancer stem cell properties of triple-negative breast cancer by simultaneously
inhibiting EGFR and PI3K signaling pathways.
Breast Cancer Res Treat. 2024 Jul 3. doi: 10.1007/s10549-024-07374. PubMedAbstract available
OZ O, Irmak Yuzuguldu R, Yazici A, Kocatepe Cavdar D, et al The differences between pure and mixed invasive micropapillary breast cancer: the
epithelial-mesenchymal transition molecules and prognosis.
Breast Cancer Res Treat. 2024 Jul 2. doi: 10.1007/s10549-024-07384. PubMedAbstract available
LEE M, Woo J, Peak SH, Kim HG, et al An exploratory clinical trial of preoperative non-invasive localization before
breast-conserving surgery using augmented reality technology.
Breast Cancer Res Treat. 2024;206:31-44. PubMedAbstract available
HONG R, Cao B, Chen D, Wu W, et al Multi-omics portrait of ductal carcinoma in situ in young women.
Breast Cancer Res Treat. 2024;206:105-118. PubMedAbstract available
LI S, Lin Y, Liu G, Shao Z, et al Unveiling the potential of breast MRI: a game changer for BI-RADS 4A
microcalcifications.
Breast Cancer Res Treat. 2024;206:425-435. PubMedAbstract available
HAAS CB, Chen H, Harrison T, Fan S, et al Disentangling the relationships of body mass index and circulating sex hormone
concentrations in mammographic density using Mendelian randomization.
Breast Cancer Res Treat. 2024;206:295-305. PubMedAbstract available
ASSAD H, Levitin M, Petrucelli N, Manning M, et al Uptake of screening and risk-reducing recommendations among women with hereditary
breast and ovarian cancer syndrome due to pathogenic BRCA1/2 variants evaluated
at a large urban comprehensive cancer center.
Breast Cancer Res Treat. 2024;206:261-272. PubMedAbstract available
SHACHAR E, Raphael A, Katz U, Kessner R, et al Body composition measures as a determinant of Alpelisib related toxicity.
Breast Cancer Res Treat. 2024;206:369-376. PubMedAbstract available
June 2024
LAMMERS SWM, Geurts SME, Hermans KEPE, van Hellemond IEG, et al Ovarian function recovery in breast cancer patients receiving adjuvant
anastrozole treatment: updated results from the phase 3 DATA trial.
Breast Cancer Res Treat. 2024 Jun 28. doi: 10.1007/s10549-024-07411. PubMedAbstract available
SHIEN T, Tsuda H, Sasaki K, Mizusawa J, et al Comparison of proportions and prognostic impact of pathological complete response
between evaluations of representative specimen and total specimen in primary
breast cancer after neoadjuvant chemoradiotherapy: an ancillary study of
JCOG0306.
Breast Cancer Res Treat. 2024 Jun 27. doi: 10.1007/s10549-024-07408. PubMedAbstract available
IWAMOTO T, Niikura N, Watanabe K, Takeshita T, et al Prognostic value of the 21-Gene Breast Recurrence Score(R) assay for hormone
receptor-positive/human epidermal growth factor 2-negative advanced breast
cancer: subanalysis from Japan Breast Cancer Research Group-M07 (FUTURE trial).
Breast Cancer Res Treat. 2024 Jun 26. doi: 10.1007/s10549-024-07414. PubMedAbstract available
CRONIN M, Lowery A, McInerney V, Wijns W, et al Understanding cardiac events in breast cancer (UCARE): pilot cardio-oncology
assessment and surveillance pathway for breast cancer patients.
Breast Cancer Res Treat. 2024 Jun 26. doi: 10.1007/s10549-024-07322. PubMedAbstract available
KIMMICK G, Pilehvari A, You W, Bonilla G, et al First- vs second-line CDK 4/6 inhibitor use for patients with hormone receptor
positive, human epidermal growth-factor receptor-2 negative, metastatic breast
cancer in the real world setting.
Breast Cancer Res Treat. 2024 Jun 26. doi: 10.1007/s10549-024-07415. PubMedAbstract available
SINGAREEKA RAGHAVENDRA A, Liu D, Shen Y, Barcenas CH, et al Outcomes of older adults with early-stage triple-negative breast cancer (TNBC)
receiving chemotherapy: a single-institution experience.
Breast Cancer Res Treat. 2024 Jun 25. doi: 10.1007/s10549-024-07309. PubMedAbstract available
MCCARTHY AM, Ehsan S, Hughes KS, Lehman CD, et al Feasibility of risk assessment for breast cancer molecular subtypes.
Breast Cancer Res Treat. 2024 Jun 25. doi: 10.1007/s10549-024-07404. PubMedAbstract available
SELIEM MA, Mohamadin AM, El-Sayed MIK, Ismail Y, et al The clinical signature of genetic variants and serum levels of macrophage
migration inhibitory factor in Egyptian breast cancer patients.
Breast Cancer Res Treat. 2024 Jun 25. doi: 10.1007/s10549-024-07393. PubMedAbstract available
ZHANG D, Fang J, Shan J, Xu L, et al SCARB2 associates with tumor-infiltrating neutrophils and predicts poor prognosis
in breast cancer.
Breast Cancer Res Treat. 2024 Jun 24. doi: 10.1007/s10549-024-07401. PubMedAbstract available
JOHNSTON E, Cowan K, MacKenzie M, Patton S, et al Identifying research priorities for improving information and support for
patients undergoing breast cancer surgery: a UK patient-centred priority setting
project.
Breast Cancer Res Treat. 2024 Jun 24. doi: 10.1007/s10549-024-07413. PubMedAbstract available
KALINSKY K, Spring L, Yam C, Bhave MA, et al Real-world use patterns, effectiveness, and tolerability of sacituzumab govitecan
for second-line and later-line treatment of metastatic triple-negative breast
cancer in the United States.
Breast Cancer Res Treat. 2024 Jun 21. doi: 10.1007/s10549-024-07412. PubMedAbstract available
WEN S, Zhang M, Chen J, Hu L, et al Characteristics of Chinese breast cancer patients with double heterozygosity for
BRCA1 and BRCA2 germline pathogenic variants.
Breast Cancer Res Treat. 2024 Jun 20. doi: 10.1007/s10549-024-07409. PubMedAbstract available
BRAVO EI, Martinez AM, Alva HP, Sancho DR, et al Reliability of Magseed(R) marking before neoadjuvant systemic therapy with
subsequent contrast-enhanced mammography in patients with non-palpable breast
cancer lesions after treatment: the MAGMA study.
Breast Cancer Res Treat. 2024 Jun 20. doi: 10.1007/s10549-024-07407. PubMedAbstract available
TEUFELSBAUER M, Stickler S, Eggerstorfer MT, Hammond DC, et al BET-directed PROTACs in triple negative breast cancer cell lines MDA-MB-231 and
MDA-MB-436.
Breast Cancer Res Treat. 2024 Jun 19. doi: 10.1007/s10549-024-07403. PubMedAbstract available
RODRIGUEZ-ROJAS K, Cortes-Reynosa P, Torres-Alamilla P, Rodriguez-Ochoa N, et al A novel role of IGFBP5 in the migration, invasion and spheroids formation induced
by IGF-I and insulin in MCF-7 breast cancer cells.
Breast Cancer Res Treat. 2024 Jun 19. doi: 10.1007/s10549-024-07397. PubMedAbstract available
LISSIDINI G, Nicosia L, Sargenti M, Cucchi MC, et al Male breast cancer: a multicenter study to provide a guide for proper management.
Breast Cancer Res Treat. 2024 Jun 19. doi: 10.1007/s10549-024-07380. PubMedAbstract available
NAKAMOTO S, Kajiwara Y, Taniguchi K, Hida AI, et al Baseline gut microbiota as a predictive marker for the efficacy of neoadjuvant
chemotherapy in patients with early breast cancer: a multicenter prospective
cohort study in the Setouchi Breast Project-14.
Breast Cancer Res Treat. 2024 Jun 18. doi: 10.1007/s10549-024-07395. PubMedAbstract available
HUPPERT LA, Fisch S, Tsopurashvili E, Somepalle SS, et al Demographic and clinical characteristics of patients with metastatic breast
cancer and leptomeningeal disease: a single center retrospective cohort study.
Breast Cancer Res Treat. 2024 Jun 18. doi: 10.1007/s10549-024-07339. PubMedAbstract available
NEVEN P, Han S, Borremans K, Van Houdt M, et al Re: Surgery of the primary tumor in patients with de novo metastatic breast
cancer: a nationwide population-based retrospective cohort study in Belgium and
the National Cancer Database (NCDB).
Breast Cancer Res Treat. 2024 Jun 16. doi: 10.1007/s10549-024-07399. PubMed
HUANG X, Chen C, Lin Y, Wang C, et al Pedigree analysis exploring the inconsistency between diverse phenotypes and
testing criteria for germline TP53 mutations in Chinese women with breast cancer.
Breast Cancer Res Treat. 2024 Jun 15. doi: 10.1007/s10549-024-07341. PubMedAbstract available
MOKHTARPOUR K, Razi S, Rezaei N Ferroptosis as a promising targeted therapy for triple negative breast cancer.
Breast Cancer Res Treat. 2024 Jun 14. doi: 10.1007/s10549-024-07387. PubMedAbstract available
JACKISCH C, Anastasiadou L, Aulmann S, Argyriadis A, et al The REMAR (Rhein-Main-Registry) real-world study: prospective evaluation of the
21-gene breast recurrence score(R) assay in addition to Ki-67 for adjuvant
treatment decisions in early-stage breast cancer.
Breast Cancer Res Treat. 2024 Jun 14. doi: 10.1007/s10549-024-07390. PubMedAbstract available
RAN X, Hu A, Kuang Y, Wang C, et al UM171 suppresses breast cancer progression by inducing KLF2.
Breast Cancer Res Treat. 2024 Jun 14. doi: 10.1007/s10549-024-07372. PubMedAbstract available
BIDISHA B, Sowmya M, Shalini S, Mythri C, et al Tamoxifen modulates nutrition deprivation-induced ER stress through AMPK-mediated
ER-phagy in breast cancer cells.
Breast Cancer Res Treat. 2024 Jun 14. doi: 10.1007/s10549-024-07398. PubMedAbstract available
BHAVE MA, Quintanilha JCF, Tukachinsky H, Li G, et al Comprehensive genomic profiling of ESR1, PIK3CA, AKT1, and PTEN in HR(+)HER2(-)
metastatic breast cancer: prevalence along treatment course and predictive value
for endocrine therapy resistance in real-world practice.
Breast Cancer Res Treat. 2024 Jun 14. doi: 10.1007/s10549-024-07376. PubMedAbstract available
ALABEDI HH, Ahmed IK, Jamil ASM Incidence of local breast cancer recurrence with delayed radiation therapy.
Breast Cancer Res Treat. 2024 Jun 14. doi: 10.1007/s10549-024-07385. PubMedAbstract available
GONCALVES E, Fontes F, Rodrigues JR, Calisto R, et al The contribution of second primary cancers to the mortality of patients with a
first primary breast cancer.
Breast Cancer Res Treat. 2024 Jun 13. doi: 10.1007/s10549-024-07361. PubMedAbstract available
VAN OLMEN JP, Schrijver AM, Stokkel MPM, Loo CE, et al Clinical implications of non-breast cancer related findings on FDG-PET/CT scan
prior to neoadjuvant chemotherapy in patients with breast cancer.
Breast Cancer Res Treat. 2024 Jun 12. doi: 10.1007/s10549-024-07331. PubMedAbstract available
ZHANG BX, Brantley KD, Rosenberg SM, Kirkner GJ, et al Second primary non-breast cancers in young breast cancer survivors.
Breast Cancer Res Treat. 2024 Jun 10. doi: 10.1007/s10549-024-07400. PubMedAbstract available
LI Y, Long W, Zhou H, Tan T, et al Revolutionizing breast cancer Ki-67 diagnosis: ultrasound radiomics and fully
connected neural networks (FCNN) combination method.
Breast Cancer Res Treat. 2024 Jun 9. doi: 10.1007/s10549-024-07375. PubMedAbstract available
HOWARD EC, Murray Horwitz ME, Gunn CM, Bak S, et al Burden and trajectory of social needs after breast cancer diagnosis at a
safety-net hospital.
Breast Cancer Res Treat. 2024 Jun 8. doi: 10.1007/s10549-024-07389. PubMedAbstract available
YIN C, Li H, Zhang B, Liu Y, et al Expression of Concern to: RAGE-binding S100A8/A9 promotes the migration and
invasion of human breast cancer cells through actin polymerization and
epithelial-mesenchymal transition.
Breast Cancer Res Treat. 2024 Jun 6. doi: 10.1007/s10549-024-07392. PubMed
FRANCOIS C, Mailliez A, Chretien S, Leguillette C, et al Therapeutic impact of (18)F-FDG PET/CT for initial staging in patients with
clinical stage I and IIA, HER2-positive, or triple-negative breast cancer.
Breast Cancer Res Treat. 2024 Jun 5. doi: 10.1007/s10549-024-07386. PubMedAbstract available
SCOTT OW, TinTin S, Cavadino A, Elwood JM, et al Beta-blocker use and breast cancer outcomes: a meta-analysis.
Breast Cancer Res Treat. 2024 Jun 5. doi: 10.1007/s10549-024-07263. PubMedAbstract available
SHI W, Xu C, Lei P, Sun X, et al A correlation study of adhesion G protein-coupled receptors as potential
therapeutic targets for breast cancer.
Breast Cancer Res Treat. 2024 Jun 4. doi: 10.1007/s10549-024-07373. PubMedAbstract available
BOYLE L, Lawrenson R, Nosa V, Campbell I, et al Ethnic inequities in use of breast conserving surgery and radiation therapy in
Aotearoa/New Zealand: which factors contribute?
Breast Cancer Res Treat. 2024;205:641-653. PubMedAbstract available
PERERA D, Pirikahu S, Walter J, Cadby G, et al The distribution of breast density in women aged 18 years and older.
Breast Cancer Res Treat. 2024;205:521-531. PubMedAbstract available
LEO CSY, Cheng LJ, Lam XR, He H, et al Global prevalence and factors associated with preoperative depression in women
undergoing breast surgery: a meta-analysis and meta-regression.
Breast Cancer Res Treat. 2024;205:425-438. PubMedAbstract available
FRANKLIN J, Hayes J, Knippa E, Dogan B, et al False negative breast cancers on imaging and associated risk factors: a single
institution six-year analysis.
Breast Cancer Res Treat. 2024;205:507-520. PubMedAbstract available
GINZAC A, Molnar I, Durando X, Motte Rouge T, et al Neoadjuvant anthracycline-based (5-FEC) or anthracycline-free
(docetaxel/carboplatin) chemotherapy plus trastuzumab and pertuzmab in HER2 + BC
patients according to their TOP2A: a multicentre, open-label, non-randomized
phase II trial.
Breast Cancer Res Treat. 2024;205:267-279. PubMedAbstract available
SHIBAHARA Y, Delabie JMA, Kulkarni S, Grant A, et al Primary MALT lymphoma of the breast: pathological and radiological
characteristics.
Breast Cancer Res Treat. 2024;205:387-394. PubMedAbstract available
MOKBEL K, Alamoodi M Reassessing treatment strategies for DCIS: analysis of survival and recurrence
patterns.
Breast Cancer Res Treat. 2024;205:423-424. PubMed
WIMMER K, Hlauschek D, Balic M, Pfeiler G, et al Is the CTS5 a helpful decision-making tool in the extended adjuvant therapy
setting?
Breast Cancer Res Treat. 2024;205:227-239. PubMedAbstract available
ELSON NC, Wernke K, Yoder LM, Fellner AN, et al Universal genetic counseling in breast cancer patients significantly improves
overall testing rates and improves completion rates in subpopulations.
Breast Cancer Res Treat. 2024 Jun 1. doi: 10.1007/s10549-024-07329. PubMedAbstract available
May 2024
ATRE SY, Soulos PR, Kuderer NM, Gross CP, et al Characterization of time toxicity in older patients with metastatic breast
cancer.
Breast Cancer Res Treat. 2024 May 31. doi: 10.1007/s10549-024-07379. PubMedAbstract available
VAN DER MERWE NC, Buccimazza I, Rossouw B, Araujo M, et al Clinical relevance of double heterozygosity revealed by next-generation
sequencing of homologous recombination repair pathway genes in South African
breast cancer patients.
Breast Cancer Res Treat. 2024 May 30. doi: 10.1007/s10549-024-07362. PubMedAbstract available
LUBARSKY M, Hernandez AE, Collie BL, Westrick AC, et al Does structural racism impact receipt of NCCN guideline-concordant breast cancer
treatment?
Breast Cancer Res Treat. 2024 May 29. doi: 10.1007/s10549-024-07245. PubMedAbstract available
REWCASTLE E, Skaland I, Gudlaugsson E, Fykse SK, et al The Ki67 dilemma: investigating prognostic cut-offs and reproducibility for
automated Ki67 scoring in breast cancer.
Breast Cancer Res Treat. 2024 May 26. doi: 10.1007/s10549-024-07352. PubMedAbstract available
ISOGAI A, Nozawa K, Nakakami A, Komaki R, et al Clinical benefit of post-trastuzumab deruxtecan treatment in patients with HER
2-positive unresectable or metastatic breast cancer: A single-institution
retrospective observational study.
Breast Cancer Res Treat. 2024 May 26. doi: 10.1007/s10549-024-07367. PubMedAbstract available
MENES TS, Zippel D, Sklair-Levy M, Friedman E, et al Clinical breast exam contribution to breast cancer diagnosis in BRCA mutation
carriers vs. average to intermediate risk women.
Breast Cancer Res Treat. 2024 May 26. doi: 10.1007/s10549-024-07345. PubMedAbstract available
SCHWIEGER L, Postlewait LM, Liu Y, Jou S, et al Changes in expression of breast cancer tumor biomarkers between primary tumors
and corresponding metastatic sites: common patterns and relationships with
survival.
Breast Cancer Res Treat. 2024 May 23. doi: 10.1007/s10549-024-07368. PubMedAbstract available
ZHUO X, Deng H, Qiu M, Qiu X, et al Pathomic model based on histopathological features and machine learning to
predict IDO1 status and its association with breast cancer prognosis.
Breast Cancer Res Treat. 2024 May 23. doi: 10.1007/s10549-024-07350. PubMedAbstract available
PEARSON A, Chen J, Dhillon HM, Kiely BE, et al Measuring serum oestrogen levels in breast cancer survivors using vaginal
oestrogens: a systematic review.
Breast Cancer Res Treat. 2024 May 23. doi: 10.1007/s10549-024-07364. PubMedAbstract available
WHITE O, Dent S, Westbrook K, Lee HJ, et al Assessment of efficacy and safety of dose-dense doxorubicin and cyclophosphamide
(ddAC) in combination with immunotherapy in early-stage triple-negative breast
cancer.
Breast Cancer Res Treat. 2024 May 21. doi: 10.1007/s10549-024-07354. PubMedAbstract available
ZHANG Y, Wang H, Zhao H, He X, et al Prognostic significance and value of further classification of lymphovascular
invasion in invasive breast cancer: a retrospective observational study.
Breast Cancer Res Treat. 2024 May 21. doi: 10.1007/s10549-024-07318. PubMedAbstract available
BARKUR S, Boitor RA, Mihai R, Gopal NSR, et al Intraoperative spectroscopic evaluation of sentinel lymph nodes in breast cancer
surgery.
Breast Cancer Res Treat. 2024 May 20. doi: 10.1007/s10549-024-07349. PubMedAbstract available
GUPTA A, Roy AM, Gupta K, Attwood K, et al Impact of environmental temperature on the survival outcomes of breast cancer: A
SEER-based study.
Breast Cancer Res Treat. 2024 May 20. doi: 10.1007/s10549-024-07369. PubMedAbstract available
TAKANO T, Masuda N, Ito M, Inoue K, et al Long-term outcomes of neoadjuvant trastuzumab emtansine + pertuzumab (T-DM1 + P)
and docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP) for HER2-positive
primary breast cancer: results of the randomized phase 2 JBCRG20 study
(Neo-peaks).
Breast Cancer Res Treat. 2024 May 20. doi: 10.1007/s10549-024-07333. PubMedAbstract available
COLE KM, McGee S, Clemons M, Liu M, et al Development and application of a weighted change score to evaluate interventions
for vasomotor symptoms in patients with breast cancer using regression trees: a
cohort study.
Breast Cancer Res Treat. 2024 May 19. doi: 10.1007/s10549-024-07360. PubMedAbstract available
STRELL C, Smith DR, Valachis A, Woldeyesus H, et al Use of beta-blockers in patients with ductal carcinoma in situ and risk of
invasive breast cancer recurrence: a Swedish retrospective cohort study.
Breast Cancer Res Treat. 2024 May 19. doi: 10.1007/s10549-024-07358. PubMedAbstract available
BOLDRINI L, Dinapoli L, Boccia E, Caliandro M, et al Coping with modesty during radiotherapy for breast cancer: a multicentric study.
Breast Cancer Res Treat. 2024 May 18. doi: 10.1007/s10549-024-07365. PubMedAbstract available
HARVIE M, Livingstone K, McMulllan D, Pegington M, et al BE-WEL trial (breast: evaluation of weight and exercise for lymphoedema) testing
weight control and exercise programmes for women with breast cancer related
lymphoedema: a feasibility trial.
Breast Cancer Res Treat. 2024 May 17. doi: 10.1007/s10549-024-07356. PubMedAbstract available
WOO JW, Han EK, Suh KJ, Kim SH, et al Alteration of PD-L1 (SP142) status after neoadjuvant chemotherapy and its
clinical significance in triple-negative breast cancer.
Breast Cancer Res Treat. 2024 May 16. doi: 10.1007/s10549-024-07359. PubMedAbstract available
SHI X, Sheng Y, Fei H, Wei B, et al Combined transcriptome and proteome analysis reveals MSN and ARFIP2 as biomarkers
for trastuzumab resistance of breast cancer.
Breast Cancer Res Treat. 2024 May 15. doi: 10.1007/s10549-024-07355. PubMedAbstract available
FREEMAN JQ, Sheade JB, Zhao F, Olopade OI, et al Racial differences in familiarity, interest, and use of integrative medicine
among patients with breast cancer.
Breast Cancer Res Treat. 2024 May 15. doi: 10.1007/s10549-024-07363. PubMedAbstract available
GIRO C, Yamada AMTD, Cruz FJSM, do R Barros LA, et al Measuring cfDNA integrity as a biomarker for predicting neoadjuvant chemotherapy
response in breast cancer patients: a pilot study.
Breast Cancer Res Treat. 2024 May 14. doi: 10.1007/s10549-024-07366. PubMedAbstract available
CORIANO M, Tommasi C, Dinh ATL, Needham J, et al The emerging predictive and prognostic role of HER2 in HER2-negative early breast
cancer: a retrospective study.
Breast Cancer Res Treat. 2024 May 14. doi: 10.1007/s10549-024-07336. PubMedAbstract available
YAMADA M, Jinno H, Naruse S, Isono Y, et al Predictive analysis of breast cancer response to neoadjuvant chemotherapy through
plasma metabolomics.
Breast Cancer Res Treat. 2024 May 13. doi: 10.1007/s10549-024-07370. PubMedAbstract available
ROSENBERG SM, Zeng C, An A, Ssebyala SN, et al Characterizing "collateral damage" in men and women with metastatic breast cancer
(mBC) from diverse racial and ethnic backgrounds in New York City.
Breast Cancer Res Treat. 2024 May 13. doi: 10.1007/s10549-024-07347. PubMedAbstract available
WU Y, Tran T, Dwabe S, Sarkissyan M, et al Retraction Note: A83-01 inhibits TGF-beta-induced upregulation of Wnt3 and
epithelial to mesenchymal transition in HER2-overexpressing breast cancer cells.
Breast Cancer Res Treat. 2024 May 10. doi: 10.1007/s10549-024-07371. PubMed
ZHANG S, Yang H, Xu Y, Wang S, et al Do we need reshape rTNM staging system for ipsilateral breast tumor recurrence of
breast cancer? A population-based, propensity score matched cohort study.
Breast Cancer Res Treat. 2024 May 10. doi: 10.1007/s10549-024-07340. PubMedAbstract available
FAIRHURST K, McIntosh SA, Cutress RI, Potter S, et al Current axillary management of patients with early breast cancer and low-volume
nodal disease undergoing primary surgery: results of a United Kingdom national
practice survey.
Breast Cancer Res Treat. 2024 May 10. doi: 10.1007/s10549-024-07328. PubMedAbstract available
KLEIN E, Kiechle M, Josipovic A, Anders SI, et al Long-term prospective outcome data using EndoPredict as risk stratification and
chemotherapy decision biomarker in hormone receptor-positive, HER2-negative early
breast cancer.
Breast Cancer Res Treat. 2024 May 9. doi: 10.1007/s10549-024-07346. PubMedAbstract available
LIN B, LeVee A, Cao L, Basho R, et al Left ventricular global longitudinal strain is worse in BRCA mutation positive
breast cancer patients prior to cancer treatment and premature menopause.
Breast Cancer Res Treat. 2024 May 8. doi: 10.1007/s10549-024-07344. PubMedAbstract available
SAINT K, Nemirovsky D, Lessing A, Chen Y, et al Impact of exercise on chemotherapy-induced peripheral neuropathy in survivors
with post-treatment primary breast cancer.
Breast Cancer Res Treat. 2024 May 7. doi: 10.1007/s10549-024-07342. PubMedAbstract available
CHEN Y, Zhang R, Yan Y, Li H, et al Effectiveness of gonadotropin-releasing hormone agonists for ovarian function
suppression in premenopausal patients with hormone receptor-positive breast
cancer: a retrospective single-center real-world study.
Breast Cancer Res Treat. 2024 May 6. doi: 10.1007/s10549-024-07323. PubMedAbstract available
RICHMAN J, Schuster G, Buus R, Lopez-Knowles E, et al Clinical and molecular predictors of very late recurrence in oestrogen
receptor-positive breast cancer patients.
Breast Cancer Res Treat. 2024 May 6. doi: 10.1007/s10549-024-07311. PubMedAbstract available
COOMBES RC, Angelou C, Al-Khalili Z, Hart W, et al Correction: Performance of a novel spectroscopy-based tool for adjuvant therapy
decision-making in hormone receptor-positive breast cancer: a validation study.
Breast Cancer Res Treat. 2024 May 5. doi: 10.1007/s10549-024-07276. PubMed
KIMURA T, Takami T, Piao Y, Ntalla I, et al Treatment patterns and clinical outcomes in patients with metastatic
triple-negative breast cancer: a large-scale data analysis using the Japanese
claims database.
Breast Cancer Res Treat. 2024 May 5. doi: 10.1007/s10549-024-07273. PubMedAbstract available
SATHE C, Accordino MK, DeStephano D, Shah M, et al Disparities in PI3K/mTOR inhibitor use, toxicities, and outcomes among patients
with metastatic breast cancer.
Breast Cancer Res Treat. 2024 May 4. doi: 10.1007/s10549-024-07337. PubMedAbstract available
CHIN K, Landen AH, Kovacs A, Warnberg F, et al Tumor-infiltrating lymphocytes as a predictor of axillary and primary tumor
pathological response after neoadjuvant chemotherapy in patients with breast
cancer: a retrospective cohort study.
Breast Cancer Res Treat. 2024 May 4. doi: 10.1007/s10549-024-07334. PubMedAbstract available
SANCHEZ-BAYONA R, Lopez de Sa A, Jerez Gilarranz Y, Sanchez de Torre A, et al Everolimus plus endocrine therapy beyond CDK4/6 inhibitors progression for
HR+ /HER2- advanced breast cancer: a real-world evidence cohort.
Breast Cancer Res Treat. 2024 May 4. doi: 10.1007/s10549-024-07324. PubMedAbstract available
BRABENDER D, Ballard A, Kim S, Hovanessian-Larsen L, et al Use of ultrasound and MRI to stage the axilla for breast cancer before and after
neoadjuvant chemotherapy prior to targeted sentinel lymphadenectomy.
Breast Cancer Res Treat. 2024 May 3. doi: 10.1007/s10549-024-07332. PubMedAbstract available
PITTELL H, Calip GS, Pierre A, Ryals CA, et al Racialized economic segregation and inequities in treatment initiation and
survival among patients with metastatic breast cancer.
Breast Cancer Res Treat. 2024 May 3. doi: 10.1007/s10549-024-07319. PubMedAbstract available
NASIF D, Laurito S, Real S, Branham MT, et al Exploring the epigenetic profile of ID4 in breast cancer: bioinformatic insights
into methylation patterns and chromatin accessibility dynamics.
Breast Cancer Res Treat. 2024 May 3. doi: 10.1007/s10549-024-07343. PubMedAbstract available
TENG YT, Wang YA, Dong YH, Liu JJ, et al Correction: Five-year survival prognosis of young, middle-aged, and elderly adult
female invasive breast cancer patients by clinical and lifestyle characteristics.
Breast Cancer Res Treat. 2024 May 2. doi: 10.1007/s10549-024-07335. PubMed
BISSELL MB, Keshavarsi S, Fleming R, Au F, et al MRI-visualized T2 hyperintense breast lesions: identifying clinical and imaging
factors linked to malignant biopsy outcomes.
Breast Cancer Res Treat. 2024;205:159-168. PubMedAbstract available
WUYTS K, Durston V, Morstyn L, Mills S, et al Information needs in breast reconstruction after mastectomy: a qualitative
analysis of free-text responses from 2077 women.
Breast Cancer Res Treat. 2024;205:147-157. PubMedAbstract available
JORGENSEN SF, Sagstad S, Louro J, Roman M, et al Comparisons of assessment pathways after abnormal mammography screening in
Denmark, Norway, and Spain.
Breast Cancer Res Treat. 2024;205:135-145. PubMedAbstract available
LUSTBERG M, Fan-Havard P, Wong FL, Hill K, et al Randomized placebo-controlled, double-blind clinical trial of nanoemulsion
curcumin in women with aromatase inhibitor-induced arthropathy: an Alliance/NCORP
pilot trial.
Breast Cancer Res Treat. 2024;205:61-73. PubMedAbstract available
April 2024
PIZZAMIGLIO S, Ciniselli CM, de Azambuja E, Agbor-Tarh D, et al Circulating microRNAs and therapy-associated cardiac events in HER2-positive
breast cancer patients: an exploratory analysis from NeoALTTO.
Breast Cancer Res Treat. 2024 Apr 30. doi: 10.1007/s10549-024-07299. PubMedAbstract available
MORAD A, Johnson K, Bate S, Birkby I, et al Ten-year trend analysis of breast cancer, oncoplastic, and reconstructive breast
surgery in a single institution (2010-2019), what has not changed?
Breast Cancer Res Treat. 2024 Apr 30. doi: 10.1007/s10549-024-07294. PubMedAbstract available
SCHAFFAR R, Benhamou S, Chappuis PO, Rapiti E, et al Risk of first recurrence after treatment in a population-based cohort of young
women with breast cancer.
Breast Cancer Res Treat. 2024 Apr 30. doi: 10.1007/s10549-024-07338. PubMedAbstract available
HIJAZI A, Mohanna M, Sabbagh S, Herran M, et al Clinico-pathologic factors and survival of patients with breast cancer diagnosed
with de novo brain metastasis: a national cancer database analysis.
Breast Cancer Res Treat. 2024 Apr 29. doi: 10.1007/s10549-024-07321. PubMedAbstract available
ROBERTS A, Hallet J, Nguyen L, Coburn N, et al Neoadjuvant chemotherapy for triple-negative and Her2 +ve breast cancer: striving
for the standard of care.
Breast Cancer Res Treat. 2024 Apr 27. doi: 10.1007/s10549-024-07282. PubMedAbstract available
YADAV SK, Bharath S, Sharma D, Srivastava A, et al A systematic review and meta-analysis of diagnostic performance of
fluorescein-guided sentinel lymph node biopsy in early breast cancer.
Breast Cancer Res Treat. 2024 Apr 26. doi: 10.1007/s10549-024-07310. PubMedAbstract available
BRADBURY M, Savard MF, Stober C, Clemons L, et al Perspectives on shorter durations of anti-HER2 therapy in early-stage
HER2-positive breast cancer: a patient survey.
Breast Cancer Res Treat. 2024 Apr 25. doi: 10.1007/s10549-024-07302. PubMedAbstract available
LEE SY, Yoo TK, Kim J, Chung IY, et al Characteristics and risk factors of axillary lymph node metastasis of
microinvasive breast cancer.
Breast Cancer Res Treat. 2024 Apr 25. doi: 10.1007/s10549-024-07305. PubMedAbstract available
SHI Y, Lu H, Zhang Y Impact of HER2 status on clinicopathological characteristics and pathological
complete response to neoadjuvant chemotherapy in triple-negative breast cancer.
Breast Cancer Res Treat. 2024 Apr 24. doi: 10.1007/s10549-024-07317. PubMedAbstract available
CHLEBOWSKI RT, Aragaki AK, Pan K, Mortimer JE, et al Randomized trials of estrogen-alone and breast cancer incidence: a meta-analysis.
Breast Cancer Res Treat. 2024 Apr 23. doi: 10.1007/s10549-024-07307. PubMedAbstract available
BERTELSEN BE, Almas B, Fjermeros K, Viste K, et al Superior suppression of serum estrogens during neoadjuvant breast cancer
treatment with letrozole compared to exemestane.
Breast Cancer Res Treat. 2024 Apr 23. doi: 10.1007/s10549-024-07313. PubMedAbstract available
LEONARD S, Jones AN, Newman L, Chavez-MacGregor M, et al Racial disparities in outcomes of patients with stage I-III triple-negative
breast cancer after adjuvant chemotherapy: a post-hoc analysis of the E5103
randomized trial.
Breast Cancer Res Treat. 2024 Apr 23. doi: 10.1007/s10549-024-07308. PubMedAbstract available
DA SILVA JL, de Albuquerque LZ, Rodrigues MES, Thuler LCS, et al Ethnic disparities in breast cancer patterns in Brazil: examining findings from
population-based registries.
Breast Cancer Res Treat. 2024 Apr 21. doi: 10.1007/s10549-024-07314. PubMedAbstract available
HSU R, Al-Zubeidy B, Flores D, Nazarian A, et al Evaluation of markers of immunity in different metastatic immune
microenvironments suggests more suppression within breast to liver metastases in
breast cancer.
Breast Cancer Res Treat. 2024 Apr 20. doi: 10.1007/s10549-024-07295. PubMedAbstract available
FERNANDEZ-GONZALEZ S, Falo C, Pla MJ, Campos M, et al Sentinel lymph node biopsy before and after neoadjuvant chemotherapy in cN0
breast cancer patients: impact on axillary morbidity and survival-a propensity
score cohort study.
Breast Cancer Res Treat. 2024 Apr 18. doi: 10.1007/s10549-024-07274. PubMedAbstract available
BALTUSSEN JC, Mooijaart SP, Vulink AJE, Houtsma D, et al Tolerability and effectiveness of palbociclib in older women with metastatic
breast cancer.
Breast Cancer Res Treat. 2024 Apr 16. doi: 10.1007/s10549-024-07312. PubMedAbstract available
TAN CF, Wang J, Zhong XR, Dai ZL, et al Is postmastectomy radiotherapy necessary for breast cancer patients with
clinically node-positive downstaging to ypN0 after neoadjuvant chemotherapy?
Breast Cancer Res Treat. 2024 Apr 15. doi: 10.1007/s10549-024-07249. PubMedAbstract available
BRANDAO M, Martins-Branco D, De Angelis C, Vuylsteke P, et al Correction: Surgery of the primary tumor in patients with de novo metastatic
breast cancer: a nationwide population-based retrospective cohort study in
Belgium.
Breast Cancer Res Treat. 2024 Apr 9. doi: 10.1007/s10549-024-07275. PubMed
FORTNER RT, Brantley KD, Tworoger SS, Tamimi RM, et al Recreational physical activity and breast cancer risk by menopausal status and
tumor hormone receptor status: results from the Nurses' Health Studies.
Breast Cancer Res Treat. 2024 Apr 9. doi: 10.1007/s10549-023-07238. PubMedAbstract available
WANG Y, Sun W, Karlsson E, Kang Lovgren S, et al Clinical evaluation of deep learning-based risk profiling in breast cancer
histopathology and comparison to an established multigene assay.
Breast Cancer Res Treat. 2024 Apr 9. doi: 10.1007/s10549-024-07303. PubMedAbstract available
RUKHSANA, Supty AT, Hussain M, Lee Y, et al STK3 higher expression association with clinical characteristics in intrinsic
subtypes of breast cancer invasive ductal carcinoma patients.
Breast Cancer Res Treat. 2024 Apr 9. doi: 10.1007/s10549-024-07248. PubMedAbstract available
SULLIVAN M, Lei X, Giordano SH, Chavez-MacGregor M, et al Breast cancer (BC) and severe COVID-19 (C-19) outcomes: a matched analysis.
Breast Cancer Res Treat. 2024 Apr 6. doi: 10.1007/s10549-024-07301. PubMedAbstract available
ALLSOPP RC, Guo Q, Page K, Bhagani S, et al Circulating tumour DNA dynamics during alternating chemotherapy and hormonal
therapy in metastatic breast cancer: the ALERT study.
Breast Cancer Res Treat. 2024 Apr 6. doi: 10.1007/s10549-024-07316. PubMedAbstract available
ALHUDIRI I, Nolan C, Ellis I, Elzagheid A, et al Expression of Cathepsin D in early-stage breast cancer and its prognostic and
predictive value.
Breast Cancer Res Treat. 2024 Apr 5. doi: 10.1007/s10549-024-07293. PubMedAbstract available
YERUSHALMI R, Pomerantz A, Lewin R, Paluch-Shimon S, et al BRCA1/2 mutation carriers vs the general breast cancer population (N = 799,986):
21-gene assay-based molecular characterization.
Breast Cancer Res Treat. 2024 Apr 3. doi: 10.1007/s10549-024-07271. PubMedAbstract available
KONTOS M, Kanavidis P, Kuhn T, Masannat Y, et al Targeted axillary dissection: worldwide variations in clinical practice.
Breast Cancer Res Treat. 2024;204:389-396. PubMedAbstract available
AI D, Turashvili G, Gjeorgjievski SG, Wang Q, et al Subspecialized breast pathologists have suboptimal interobserver agreement in
Ki-67 evaluation using 20% as the cutoff.
Breast Cancer Res Treat. 2024;204:415-422. PubMedAbstract available
COBLEIGH MA, Layng KV, Mauer E, Mahon B, et al Comparative genomic analysis of PIK3R1-mutated and wild-type breast cancers.
Breast Cancer Res Treat. 2024;204:407-414. PubMedAbstract available
BAHL M, Deng B Impact of pre-operative MRI on surgical management of screening digital breast
tomosynthesis-detected invasive lobular carcinoma.
Breast Cancer Res Treat. 2024;204:397-405. PubMedAbstract available
WALSH EA, Post K, Massad K, Horick N, et al Identification of patient subgroups who benefit from a behavioral intervention to
improve adjuvant endocrine therapy adherence: a randomized-controlled trial.
Breast Cancer Res Treat. 2024;204:547-559. PubMedAbstract available
FLETCHER KA, Alkurashi MH, Lindsay AJ Endosomal recycling inhibitors downregulate estrogen receptor-alpha and synergise
with endocrine therapies.
Breast Cancer Res Treat. 2024;204:631-642. PubMedAbstract available
WANG H, Yee D, Potter D, Jewett P, et al Impact of body mass index on pathological response after neoadjuvant
chemotherapy: results from the I-SPY 2 trial.
Breast Cancer Res Treat. 2024;204:589-597. PubMedAbstract available
VAN HEMERT A, van Loevezijn AA, Bosman A, Vlahu CA, et al Breast surgery after neoadjuvant chemotherapy in patients with lobular carcinoma:
surgical and oncologic outcome.
Breast Cancer Res Treat. 2024;204:497-507. PubMedAbstract available
HARDY-ABELOOS C, Xiao J, Oh C, Barbee D, et al Effectiveness and toxicity of five-fraction prone accelerated partial breast
irradiation.
Breast Cancer Res Treat. 2024;204:485-495. PubMedAbstract available
BLOMQVIST C, Vehmanen L, Kellokumpu-Lehtinen PL, Huovinen R, et al Long-term effects of aromatase inhibitor withdrawal on bone mineral density in
early breast cancer patients: 10-year follow-up results of the BREX study.
Breast Cancer Res Treat. 2024 Apr 1. doi: 10.1007/s10549-024-07252. PubMedAbstract available
MARTINEZ-JANEZ N, Ezquerra MB, Manso Sanchez LM, Carrasco FH, et al First-line therapy with palbociclib in patients with advanced HR(+)/HER2(-)
breast cancer: The real-life study PALBOSPAIN.
Breast Cancer Res Treat. 2024 Apr 1. doi: 10.1007/s10549-024-07287. PubMedAbstract available
March 2024
CAMPBELL EK, Campbell TM, Culakova E, Blanchard L, et al A whole food, plant-based randomized controlled trial in metastatic breast
cancer: feasibility, nutrient, and patient-reported outcomes.
Breast Cancer Res Treat. 2024 Mar 30. doi: 10.1007/s10549-024-07284. PubMedAbstract available
BURO AW, Nguyen T, Abaskaron M, Haver MK, et al Lifestyle interventions with dietary strategies after breast cancer diagnosis: a
systematic review.
Breast Cancer Res Treat. 2024 Mar 29. doi: 10.1007/s10549-024-07278. PubMedAbstract available
GULIYEV M, Sen GA, Gulturk I, Majidova N, et al The effects of low HER2 expression on survival in patients with metastatic breast
cancer treated with CDK 4/6 inhibitors: a multicenter retrospective study.
Breast Cancer Res Treat. 2024 Mar 25. doi: 10.1007/s10549-024-07291. PubMedAbstract available
JUNG JJ, Cheun JH, Kim HK, Lee HB, et al Comparison of long-term oncologic outcomes of central lumpectomy and conventional
breast-conserving surgery for invasive breast cancer: propensity score matching
analysis.
Breast Cancer Res Treat. 2024 Mar 25. doi: 10.1007/s10549-024-07297. PubMedAbstract available
TENG YT, Wang YA, Dong YH, Liu JJ, et al Five-year survival prognosis of young, middle-aged, and elderly adult female
invasive breast cancer patients by clinical and lifestyle characteristics.
Breast Cancer Res Treat. 2024 Mar 25. doi: 10.1007/s10549-024-07280. PubMedAbstract available
KAPLAN HG, Dowdell AK, Berry AB, Shimol RB, et al Multi-omic profiling of simultaneous ductal carcinoma in situ and invasive breast
cancer.
Breast Cancer Res Treat. 2024 Mar 24. doi: 10.1007/s10549-024-07270. PubMedAbstract available
GODINEZ PAREDES JM, Rodriguez I, Ren M, Orozco A, et al Germline pathogenic variants associated with triple-negative breast cancer in US
Hispanic and Guatemalan women using hospital and community-based recruitment
strategies.
Breast Cancer Res Treat. 2024 Mar 23. doi: 10.1007/s10549-024-07300. PubMedAbstract available
DOUBBLESTEIN D, Koehler L, Anderson E, Scheiman N, et al Development of a core set of outcome measures to be applied toward breast
cancer-related lymphedema core outcome domains.
Breast Cancer Res Treat. 2024 Mar 22. doi: 10.1007/s10549-024-07298. PubMedAbstract available
COLLIN LJ, Jones J, Nash R, Switchenko JM, et al Racial disparities in initiation of chemotherapy among breast cancer patients
with discretionary treatment indication in the state of Georgia.
Breast Cancer Res Treat. 2024 Mar 22. doi: 10.1007/s10549-024-07279. PubMedAbstract available
NASIRI N, Hu M, Hajizadeh M Trends in socioeconomic inequalities in breast cancer mortality in Canada:
1992-2019.
Breast Cancer Res Treat. 2024 Mar 19. doi: 10.1007/s10549-024-07277. PubMedAbstract available
AUGUSTINSSON A, Loman N, Ehrencrona H Retrospective genetic testing (Traceback) in women with early-onset breast cancer
after revised national guidelines: a clinical implementation study.
Breast Cancer Res Treat. 2024 Mar 16. doi: 10.1007/s10549-024-07288. PubMedAbstract available
WU Q, Hatse S, Kenis C, Fernandez-Garcia J, et al Aging-accumulated methylmalonic acid serum levels at breast cancer diagnosis are
not associated with distant metastases.
Breast Cancer Res Treat. 2024 Mar 13. doi: 10.1007/s10549-024-07260. PubMedAbstract available
CHUNG HL, Middleton LP, Sun J, Whitman GJ, et al Immediate and delayed risk of breast cancer associated with classic lobular
carcinoma in situ and its variants.
Breast Cancer Res Treat. 2024 Mar 12. doi: 10.1007/s10549-024-07261. PubMedAbstract available
FARLAND LV, Lind KE, Thomson CA, Saquib N, et al Infertility and risk of postmenopausal breast cancer in the women's health
initiative.
Breast Cancer Res Treat. 2024 Mar 9. doi: 10.1007/s10549-024-07257. PubMedAbstract available
GION M, Garcia-Mosquera JJ, Perez-Garcia JM, Peg V, et al Correlation between trophoblast cell-surface antigen-2 (Trop-2) expression and
pathological complete response in patients with HER2-positive early breast cancer
treated with neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab.
Breast Cancer Res Treat. 2024 Mar 8. doi: 10.1007/s10549-024-07292. PubMedAbstract available
AVILA J, Leone J, Vallejo CT, Lin NU, et al Survival analysis of patients with brain metastases at initial breast cancer
diagnosis over the last decade.
Breast Cancer Res Treat. 2024 Mar 7. doi: 10.1007/s10549-024-07290. PubMedAbstract available
GARCIA-TORRALBA E, Perez Ramos M, Ivars Rubio A, Navarro Manzano E, et al Deconstructing neutrophil to lymphocyte ratio (NLR) in early breast cancer: lack
of prognostic utility and biological correlates across tumor subtypes.
Breast Cancer Res Treat. 2024 Mar 7. doi: 10.1007/s10549-024-07286. PubMedAbstract available
BAYRAKCEKEN E, Yarali S, Alkan O Identify risk factors affecting participation of Turkish women in mammography
screening for breast cancer prevention.
Breast Cancer Res Treat. 2024 Mar 7. doi: 10.1007/s10549-024-07296. PubMedAbstract available
FINSTERBUSCH K, van Diest PJ, Focke CM Intertumoral heterogeneity of bifocal breast cancer: a morphological and
molecular study.
Breast Cancer Res Treat. 2024 Mar 7. doi: 10.1007/s10549-024-07281. PubMedAbstract available
CAMPBELL TM, Campbell EK, Culakova E, Blanchard LM, et al A whole-food, plant-based randomized controlled trial in metastatic breast
cancer: weight, cardiometabolic, and hormonal outcomes.
Breast Cancer Res Treat. 2024 Mar 6. doi: 10.1007/s10549-024-07266. PubMedAbstract available
SUN H, Kang EY, Chen H, Sweeney KJ, et al Immunohistochemical assessment of HER2 low breast cancer: interobserver
reproducibility and correlation with digital image analysis.
Breast Cancer Res Treat. 2024 Mar 5. doi: 10.1007/s10549-024-07256. PubMedAbstract available
PLICHTA JK, Thomas SM, Wang X, McDuff SGR, et al Survival among patients with untreated metastatic breast cancer: "What if I do
nothing?".
Breast Cancer Res Treat. 2024 Mar 5. doi: 10.1007/s10549-024-07265. PubMedAbstract available
KULOTHUNGAN V, Ramamoorthy T, Sathishkumar K, Mohan R, et al Burden of female breast cancer in India: estimates of YLDs, YLLs, and DALYs at
national and subnational levels based on the national cancer registry programme.
Breast Cancer Res Treat. 2024 Mar 4. doi: 10.1007/s10549-024-07264. PubMedAbstract available
WU Y, Li Z, Lee AV, Oesterreich S, et al Liver tropism of ER mutant breast cancer is characterized by unique molecular
changes and immune infiltration.
Breast Cancer Res Treat. 2024 Mar 1. doi: 10.1007/s10549-024-07255. PubMedAbstract available
February 2024
DOUBBLESTEIN D, Koehler L, Anderson E, Scheiman N, et al Development of a core outcome set for breast cancer-related lymphedema: a Delphi
study.
Breast Cancer Res Treat. 2024 Feb 29. doi: 10.1007/s10549-024-07262. PubMedAbstract available
HOSSEINI Y, Hadi Sichani P, Moslemi E, Nouri M, et al Pro-vegetarian dietary pattern and risk of breast cancer: a case-control study.
Breast Cancer Res Treat. 2024 Feb 28. doi: 10.1007/s10549-024-07243. PubMedAbstract available
VOETS MM, Hassink NS, Veltman J, Slump CH, et al Opportunities for personalised follow-up in breast cancer: the gap between daily
practice and recurrence risk.
Breast Cancer Res Treat. 2024 Feb 26. doi: 10.1007/s10549-024-07246. PubMedAbstract available
December 2023
PACE LE, Fata AM, Cubaka VK, Nsemgiyumva T, et al Patients' experiences undergoing breast evaluation in Rwanda's Women's Cancer
Early Detection Program.
Breast Cancer Res Treat. 2023;202:541-550. PubMedAbstract available
TURASHVILI G, Gjeorgjievski SG, Wang Q, Ewaz A, et al Intraoperative assessment of axillary sentinel lymph nodes by telepathology.
Breast Cancer Res Treat. 2023;202:423-434. PubMedAbstract available